Antiplexin a1 agonist antibody

ABSTRACT

Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

TECHNICAL FIELD

The present invention relates to an anti-Plexin-A1 agonist antibody and use thereof.

BACKGROUND ART

Semaphorins were discovered in the early 1990's as repulsive molecules for neuronal growth cones (Non Patent Literatures 1 and 2). More than 20 members of semaphorins have been identified to date, and the semaphorin family is characterized by sharing a conserved region consisting of about 500 amino acids, referred to as the Sema domain. These semaphorins are classified into eight sub-classes (Sema 1-7, V) on the basis of structural difference at the C-terminus following the Sema domain.

Plexins (Plexin-A1/A2/A3/A4, Plexin-B1/B2/B3, Plexin-C1, and Plexin-D1) and neuropilins (Nrp-1 and Nrp-2) are known as major receptors that contribute to the semaphorin activity. Semaphorins are known to also bind to integrins, CD72, and Tim-2 (Non Patent Literature 3). Furthermore, the semaphorin receptors, plexins, are known to associate with various co-receptors such as VEGFR-2, c-Met, and Trem2/DAP12, and construct complex ligand-receptor relationships, which possibly reflect diverse functions of the semaphorins. Indeed, the semaphorins have diverse biological activities such as angiogenesis/vasculogenesis, cancer metastasis/invasion, bone metabolism regulation, retinal homeostasis, and immune regulation, and the involvement of the semaphorins in various diseases such as allergic diseases or autoimmune diseases, metabolic bone diseases, neurodegenerative diseases, retinitis pigmentosa, sudden death from cardiac causes, and cancer metastasis/invasion has been successively reported in the past several years (Non Patent Literature 3). In connection with biological activities of the semaphorins, active research is currently ongoing with a view towards developing diagnostic/therapeutic methods for human diseases.

Plexin-A1 is a receptor for class III and class VI semaphorins. Plexin-A1 has been reported to form receptors together with VEGF receptor and Off-Track during chick heart morphogenesis, and also act as a receptor for neuronal repulsive factors by forming a receptor for class III semaphorins together with Nrp-1. Furthermore, Plexin-A1 has been reported to also act as a receptor for class VI semaphorins, Sema6C and Sema6D, and be involved in axon guidance or cardiac organogenesis.

It has been reported that suppression of Plexin-A1 expression by shRNA in mouse dendritic cells, for example, leads to attenuated non-autoimmune T-cell immunity in vivo or in vitro (Non Patent Literature 4). Plexin-A1 signal analysis in dendritic cells and osteoclasts has also confirmed that Plexin-A1 forms heteroreceptors with Trem-2 and DAP-12 in these cells. It has also been shown that recombinant soluble Sema6D protein stimulation promotes the expression of inflammatory cytokines such as IL-12 from dendritic cells and osteoclast differentiation from precursor cells, and that while Sema6D binds to wild-type dendritic cells, it hardly binds to dendritic cells from Plexin-A1-deficient mice. It has been reported that T-cell immune responses are significantly weaker in Plexin-A1-deficient mice, which spontaneously develops osteopetrosis-like symptoms caused by abnormal osteoclast differentiation (Non Patent Literature 5). Plexin-A1 inhibition by shRNA in mouse dendritic cells has shown that Plexin-A1 controls actin cytoskeleton localization in the immune synapses of dendritic cells and T cells via activation of signal transduction factor Rho (Non Patent Literature 6).

Furthermore, it has been reported that Plexin-A1 is involved in the migration of dendritic cells to the lymph nodes and in antigen-specific T-cell responses. It has also been reported that the expression of Sema3A, rather than Sema6C or Sema6D, is required for migration of dendritic cells as they pass through the endothelial cells of the lymphatic vessels, and Sema3A stimulates myosin-II activity and induce actomyosin contraction (Patent Literature 1).

Furthermore, in connection with Plexin-A2, which is another molecule belonging to the Plexin-A family, a low-resolution (7.0 A) structure of a triple complex, “Sema3A-Plexin-A2-Nrp-1”, has been disclosed. Although the binding between Sema3A and Plexin-A2 is too weak to be detected, it has been reported that an interaction between Sema3A and Plexin-A2 was detected in the presence of Nrp-1, even though it was far too weak for the expression of biological activity of Sema3A (Non Patent Document 7). The elucidation of this complex, however, requires further detailed study, because the resolution of this structure is extremely low, and a partial-length protein rather than a full-length protein was used. Non Patent Literature 8, on the other hand, introduces the structure of a triplet complex, “Sema3A-Plexin-A1-Nrp-1”, citing Non Patent Literature 7 described above. Non Patent Literature 7, however, fails to disclose the structure of the triplet complex “Sema3A-Plexin-A1 -Nrp-1”.

Sema3A has been suggested to exhibit therapeutic effects against various diseases such as autoimmune diseases including pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus, inflammatory diseases, and tumors, mainly through expression analysis in patients and experiments with animal models.

For example, decreased expression of Sema3A has been reported in the skin of patients with psoriasis or atopic dermatitis (Non Patent Literatures 9 and 10). Sema3A has inhibitory activity on C-fiber neurite outgrowth. In the skin of patients with psoriasis or atopic dermatitis, the decreased expression of Sema3A induces the outgrowth of C-fiber neurites, which is believed to result in susceptibility to itchiness. Indeed, the application of Sema3A to the skin of atopic dermatitis mouse models through intradermal administration or as an ointment has been reported to improve pruritic behavior caused by atopic dermatitis (Non Patent Literatures 11 and 12).

Sema3A has also been reported to be involved in airway hyperreactivity in allergic rhinitis, for example (Non Patent Literature 13). The expression of Sema3A decreases in epithelial cells in the nasal cavity of allergic rhinitis mouse models, which leads to an increased innervation density in the nasal turbinate lamina propria. This is believed to be one cause of the exacerbation of hypersensitivity such as sneezing and itching. Intranasal administration of Sema3A to allergic rhinitis mouse models has been reported to reduce the innervation density in the nasal turbinate lamina propria, and improve sneezing or pruritic behavior.

Furthermore, Sema3A is known to be also involved in the control of bone density. Sema3A has an activity to both activate osteoblasts and suppress osteoclast differentiation in vitro, and mice with systemic Sema3A deficiency develop osteoporosis-like symptoms. Furthermore, the administration of Sema3A to mouse models in which osteoporosis-like symptoms were induced by oophorectomy has been reported to improve the bone density (Non Patent Literature 14). In addition to the direct action of Sema3A upon osteoblasts and osteoclasts, a Sema3A-mediated bone density control mechanism through sensory innervation to bone has also been reported. In neuron-specific Sema3A-deficient mice, an osteoporosis-like decrease in bone density comparable to that in mice with systemic Sema3A deficiency has been reported (Non Patent Literature 5).

Furthermore, Sema3A has been reported to be involved in autoimmune diseases and inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. For example, there is a report that, compared to normal human peripheral blood, the peripheral blood of rheumatoid arthritis patients shows a decrease in the level of Sema3A mRNA or protein produced upon in vitro activation of peripheral mononuclear blood cells (PBMCs), CD4-positive T cells, and CD8-positive T cells with anti-CD3 antibody and anti-CD28 antibody. Likewise, a decrease in the mRNA expression of Sema3A has been reported in rheumatoid arthritis patient-derived synovial tissue, compared to healthy human-derived synovial tissue. Furthermore, intraperitoneal administration of plasmids encoding Sema3A protein to collagen-induced arthritis mouse models has been reported to show an improvement in arthritis score or an improvement in hindlimb swelling (Non Patent Literature 16).

It has also been reported that the Sema3A concentration in the peripheral blood of systemic lupus erythematosus patients is significantly lower than that in the peripheral blood of healthy humans, and that in CD19+CD25^(high) B cells collected from the peripheral blood of systemic lupus erythematosus patients, the expression of Sema3A is lower than that in the same cells collected from healthy individuals, which suggests the possibility that this change in the expression level of Sema3A in systemic lupus erythematosus patients may affect the activation of B cells (Non Patent Literature 17).

Furthermore, the expression of Sema3A has been reported to be lower in malignant melanoma skin tissues from melanoma patients than that in normal skin tissues. It has also been reported that murine malignant melanoma cell lines in which the Sema3A gene was transfected and stably expressed exhibit reduced migration and invasiveness of tumor cells in vitro and increased sensitivity to anti-cancer agents, compared to parental cell lines not transfected with the Sema3A gene. Likewise, in mouse models injected subcutaneously with tumor cells, murine malignant melanoma cell lines in which the Sema3A gene was transfected and stably expressed have been reported to exhibit suppressed tumor metastasis and retarded tumor growth, compared to parental cell lines not transfected with the Sema3A gene (Non Patent Literature 18).

These reports have suggested the utility of Sema3A as a therapeutic drug for various diseases such as autoimmune diseases including pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus, inflammatory diseases, and tumors.

However, no report has heretofore been made on an antibody that binds to one of the receptors, Plexin-A1, and has an activity similar to that of Sema3A (agonist antibody). Furthermore, it has been unclear as to which region of the amino acid sequence of Plexin-A1 is bound by the antibody that binds to Plexin-A1 and has agonistic activity.

CITATION LIST Non Patent Literature

Non Patent Literature 1: Kolodkin, A L. et al., Cell, 75, 1389-1399 (1993)

-   Non Patent Literature 2: Tessier-Lavigne, M. et al., Science, 274,     1123-1133 (1996) -   Non Patent Literature 3: Pasterkamp, R J. et al., Curr. Opin.     Neurobiol., 13, 79-89 (2003) -   Non Patent Literature 4: Wong A W et al., Nat. Immunol., 4(9),     891-898 (2003) -   Non Patent Literature 5: Takegahara N. et al., Nat. Cell. Biol., 8,     615-622 (2006) -   Non Patent Literature 6: Eun S Y et al., J. Immunol., 177(7),     4271-4275 (2006) -   Non Patent Literature 7: Janssen. B. J. et al., Nat. Struct. Mol.     Biol., 19, 1293-1299 (2012) -   Non Patent Literature 8: Yukiko Matsunaga et al., The Journal of     Experimental Medicine 31 (4), 523-530 (2013) -   Non Patent Literature 9: Kouo, K. et al., Acta Derm. Venereol., 92,     521-528 (2012) -   Non Patent Literature 10: Tominaga, M. et al., Journal of     Dermatological Science, 55, 40-46 (2009) -   Non Patent Literature 11: Yamaguchi, J. et al., Journal of     Investigative Dermatology, 128, 2842-2849 (2008) -   Non Patent Literature 12: Negi, O. et al., Journal of Dermatological     Science, 66, 37-43 (2012) -   Non Patent Literature 13: Sawaki, H. et al., J. Pharmacol. Sci.,     117, 34-44 (2011) -   Non Patent Literature 14: Hayashi, M. et al., Nature, 485, 69-74     (2012) -   Non Patent Literature 15: Fukuda, T. et al., Nature, 497, 490-493     (2013) -   Non Patent Literature 16: Catalano, A., The Journal of Immunology,     185, 6373-83 (2010) -   Non Patent Literature 17: Vadasz, Z. et al., Arthritis Research &     Therapy, 14, R146 (2012) -   Non Patent Literature 18: Chakraborty, G. et al., PLoS ONE, 7(3),     e33633 (2012)

SUMMARY OF INVENTION Technical Problem

The present invention was made in view of the aforementioned circumstances, and an object of the present invention is to provide a novel anti-Plexin-A1 agonist antibody, a pharmaceutical composition containing the agonist antibody, a prophylactic and/or therapeutic agent for diseases associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, which contains the pharmaceutical composition, and a kit therefor.

Solution to Problem

-   As a result of extensive research to solve the aforementioned     problem, the present inventors successfully acquired a novel     anti-Plexin-A1 agonist antibody. The present inventors also found     that the anti-Plexin-A1 agonist antibody recognizes an epitope     present in a region of Plexin-A1 different from that of an     anti-Plexin-A1 antagonist antibody. The present invention was     accomplished on the basis of this finding, and relates to the     following [1] to [15]: -   [1] An anti-Plexin-A1 agonist antibody. -   [2] The antibody according to [1], which has a class 3     semaphorin-like activity. -   [3] The antibody according to [2], wherein the class 3     semaphorin-like activity is a semaphorin 3A-like activity. -   [4] The antibody according to [2] or [3], wherein the class 3     semaphorin-like activity is an activity to promote dendritic cell     contraction or glioma cell contraction. -   [5] The antibody according to any of [1] to [4], which specifically     binds to an epitope in a sema domain of Plexin-A1. -   [6] The antibody according to [5], wherein the epitope in the sema     domain is an epitope in a C-terminal region of the sema domain. -   [7] The antibody according to [6], wherein the C-terminal region is     for binding to residues 461-514 of SEQ ID NO: 3 or residues 459-512     of SEQ ID NO: 52. -   [8] The antibody according to any of [1] to [7], which cross-reacts     with human Plexin-A1 and mouse Plexin-A1. -   [9] The antibody according to any of [1] to [8], which is a     monoclonal antibody. -   [10] The antibody according to any of claims [1] to [9], which is a     chimeric antibody, a humanized antibody, or a human antibody. -   [11] The antibody according to any of [1] to [10], which is Fab,     scFv, F(ab')2, a single-chain antibody, or a bispecific     antibody.[12] A pharmaceutical composition comprising the antibody     according to any of [1] to [11] and a pharmaceutically acceptable     carrier. -   [13] A method for producing a pharmaceutical composition comprising     mixing the antibody according to any of [1] to [11] and a     pharmaceutically acceptable carrier. -   [14] The pharmaceutical composition according to [12], which is for     use in prevention and/or treatment of diseases associated with a     quantitative or qualitative decrease in function of a class 3     semaphorin. -   [15] A kit comprising the antibody according to any of [1] to [11]     or the pharmaceutical composition according to [12] or [14] and     instructions for administering the antibody or pharmaceutical     composition for preventing and/or treating diseases associated with     a quantitative or qualitative decrease in function of a class 3     semaphorin.

Advantageous Effects of Invention

According to the present invention, there are provided a novel anti-Plexin-A1 agonist antibody, a pharmaceutical composition containing the agonist antibody, a prophylactic and/or therapeutic agent for diseases associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, which contains the pharmaceutical composition, and a kit therefor.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 illustrates a plot showing values of cell contraction upon 5-hour stimulation of mouse bone marrow-derived dendritic cells with mouse semaphorin 3A.

FIG. 2 illustrates plots each showing the binding activity of anti-mouse PlexinA1 antibody, PXB361b, PXB693, or PXB727, to mouse PlexinA1. The X-axis represents the antibody concentration, and the Y-axis represents the absorbance at a wavelength of 405 nm. The solid line represents binding to the Ba/F3 cell line expressing a high level of mouse PlexinA1, and the dashed line represents binding to Ba/F3 cells.

FIG. 3 illustrates plots each showing dose-dependent antagonistic activity of a control antibody or anti-PlexinA1 antibody (rabbit IgG) at concentrations of 0 to 100 ug/mL against semaphorin 3A-dependent mouse bone marrow-derived dendritic cell contraction.

FIG. 4 illustrates a plot showing absorbance values of binding responses of antibodies bound to BaF3 cells expressing human PlexinA1 or mouse PlexinA1 on the cell membrane surface.

FIG. 5 illustrates a plot showing binding responses measured by immobilizing mouse chimeric antibodies hPANL#240-mFc, 359B-2-2-3-6-mFc, PXB693-mFc, PXB727-mFc, and PXB361b-mFc onto Protein G biosensors, and applying human PlexinA1 and mouse PlexinA1 thereto.

FIG. 6 illustrates a plot showing the results obtained by immobilizing PXB693 onto Protein G biosensors and applying antigen, and then further applying the various antibodies, thereby evaluating whether the various antibodies compete for binding. Competition ratios of the various antibodies relative to PXB693 are shown.

FIG. 7 illustrates a plot showing changes in Cell index value upon 1-hour stimulation of U87-MG cells with human semaphorin 3A using the xCELLigence system.

FIG. 8 illustrates plots showing dose-dependent semaphorin 3A-like agonistic activities of anti-PlexinA1 antibodies for mouse bone marrow-derived dendritic cell contraction. Sema3A(+) represents values measured with the addition of 0.8 μg/mL of mouse semaphorin 3A, and Sema3A(−) represents values measured without the addition of mouse semaphorin 3A.

FIG. 9 illustrates plots showing semaphorin 3A-like agonistic activities of anti-PlexinA1 antibodies against U87-MG cells. Sema3A(+) represents values measured with the addition of 1.6 μg/mL of human semaphorin 3A.

FIG. 10A illustrates a plot showing binding affinities of the antagonist antibody mouse chimera PXB361b for mouse PlexinA1, mouse PleixinA2, and the chimeric protein of mouse PlexinA1 and PlexinA2. 1: Mouse PlexinA1 sema domain, 2: mouse PlexinA1/A2 sema domain chimera, 3: mouse PlexinA2 sema domain, Control Ab: control antibody, PXB361b: mouse chimeric antibody PXB361b-mFc.

FIG. 10B illustrates a plot showing binding affinities of the agonist antibody mouse chimeras PXB693 and PXB727 for mouse PlexinA1, mouse PleixinA2, and the chimeric protein of mouse PlexinA1 and PlexinA2. 1: Mouse PlexinA1 sema domain, 2: mouse PlexinA1/A2 sema domain chimera, 3: mouse PlexinA2 sema domain, Control Ab: control antibody, PXB693: mouse chimeric antibody PXB693-mFc, PBX727-mFc: mouse chimeric antibody PXB727.

FIG. 11 illustrates a comparison of amino acid sequences between the mouse PlexinA1 sema domain and the mouse PlexinA2 sema domain. A site used for the preparation of the mouse PlexinA1/A2 chimeric protein is underlined.

FIG. 12 illustrates a comparison of amino acid sequences between the mouse PlexinA1 sema domain and the human PlexinA1 sema domain. A site used for the preparation of the mouse PlexinA1/A2 chimeric protein is underlined.

DESCRIPTION OF EMBODIMENTS Plexin-A1

Plexin-A1 may be human or murine Plexin-A1, for example, although not particularly limited thereto. The amino acid sequence and nucleotide sequence of murine Plexin-A1 are published in, for example, Kameyama T et al. “Biochemical and biophysical research communications.”; Biochem Biophys Res Commun. 1996, 226(2), 524-9; and Accession No. D86948, NCBI Reference Sequence NP_032907.1 from Genbank. The amino acid sequence and nucleotide sequence of human Plexin-A1 are published in, for example, Tamagnone L et al. Cell. 1999, 99(1), 71-80; Accession No. X87832, NCBI Reference Sequence NP_115618.3 from Genbank; and NCBI Reference Sequence NM_032242. Plexin-A1 can be readily cloned on the basis of the above-described sequence information. The amino acid sequence or nucleotide sequence of Plexin-A1 can be modified, as appropriate, within the scope of the intended use. The amino acid sequence of Plexin-A1 is well-conserved between humans and mice. As used herein, the term “Plexin-A1 ” is also designated as PlexinA1 or PlxnA1. Furthermore, the simple recitation “Plexin-A1 ” refers to human and/or murine Plexin-A1 , and the same holds true for other factors (e.g., semaphorin 3A).

Anti-Plexin-A1 Agonist Antibody

The anti-Plexin-A1 agonist antibody refers to, for example, an antibody that specifically binds to the Plexin-A1 protein and has Plexin-A1-mediated signaling activity, including, for example, an antibody having a class 3 semaphorin-like activity.

The class 3 semaphorin-like activity refers to at least one of the activities that can be exhibited by a class 3 semaphorin in vitro or in vivo, and is preferably a semaphorin 3A-like activity, i.e., at least one of the activities that can be exhibited by semaphorin 3A in vitro or in vivo. For example, this activity refers to an activity transduced by a complex of semaphorin 3A, neuropilin-1, and Plexin-A1. The activity as used herein includes promoting activity and suppressing activity. Furthermore, the activity transduced by the complex of semaphorin 3A, neuropilin-1, and Plexin-A1 refers to, for example, an activity transduced when semaphorin 3A forms a ternary complex with neuropilin-1 and Plexin-A1. Specific examples of semaphorin 3A-like activities include a cell contraction-promoting activity, for example, a dendritic cell or glioma cell contraction-promoting activity. Examples of glioma cells include human glioblastoma-derived cells and human glioblastoma/astrocytoma-derived cells, and specifically, U-87 MG cells.

One embodiment of the anti-Plexin-A1 agonist antibody of the present invention may be, for example, an antibody having a cell contraction-promoting activity, for example, an antibody having a dendritic cell or glioma cell contraction-promoting activity. The recitation “having an activity” includes the meaning “enhancing the activity”.

Anti-Plexin-A1 Antagonist Antibody

The anti-Plexin-A1 antagonist antibody refers to, for example, an antibody that specifically binds to the Plexin-A1 protein to prevent or attenuate the Plexin-A1-mediated signaling activity, including, for example, an antibody that prevents or attenuates the class 3 semaphorin-like activity, and preferably an antibody that prevents or attenuates the semaphorin 3A-like activity. Examples of the anti-Plexin-A1 agonist antibody include an antibody that inhibits cell contraction, which is specifically an antibody that inhibits dendritic cell or glioma cell contraction.

Class 3 Semaphorins

More than 20 members of semaphorins have been identified to date, and the semaphorin family is characterized by sharing a conserved region consisting of about 500 amino acids, referred to as the Sema domain. These semaphorins are classified into eight sub-classes on the basis of structural difference at the C-terminus following the Sema domain. Sema3A, Sema3B, Sema3C, Sema3D, Sema3E, and Sema3F are known as class 3 semaphorins. As used herein, the term “class 3 semaphorins” includes Sema3A, Sema3B, Sema3C, Sema3D, Sema3E, and Sema3F, with Sema3A (semaphorin 3A) being preferred.

Semaphorin 3A

Semaphorin 3A may be human or murine semaphorin 3A, although not particularly limited thereto. The amino acid sequence of human semaphorin 3A is published in NCBI Reference Sequence NP_006071.1, for example. The amino acid sequence of murine semaphorin 3A is published in NP_033178.2, for example. Semaphorin 3A can be readily cloned on the basis of the above-described sequence information. The amino acid sequence of semaphorin 3A can be modified, as appropriate, within the scope of the intended use. Semaphorin 3A is herein also designated as Sema3A.

Sema Domain

The sema domain typically corresponds to positions 51 to 487 of SEQ ID NO: 3 in human Plexin-A1 , positions 49 to 485 of SEQ ID NO: 52 in mouse Plexin-A1 , and positions 50 to 483 of SEQ ID NO: 53 in mouse Plexin-A2.

Semaphorin 3A-Like Activity

The semaphorin 3A-like activity as one preferred example of the class 3 semaphorin-like activity specifically refers to, for example, the following activities: a cell (e.g., dendritic cell)-contracting activity; an activity to promote migration of dendritic cells to Draining Lymph Node (U.S. Patent Application Publication No. 2012/0322085); an osteoclast differentiation-suppressing activity and an osteoblast differentiation-promoting activity (Hayashi M et al., Nature, 2012, 485, 69-74); and a neuronal outgrowth inhibitory activity (U.S. Pat. No. 7,642,362). The agonist antibody of the present invention may have at least one of the class 3 semaphorin-like activities. For example, the agonist antibody of the present invention promotes cell contraction, and, for example, promotes dendritic cell or glioma cell contraction. The antagonist antibody may inhibit at least one of the class 3 semaphorin-like activities. For example, the antagonist antibody inhibits cell contraction, and, for example, inhibits dendritic cell or glioma cell contraction.

The recitation “has”, “have”, or “having” the class 3 semaphorin-like activity means that the class 3 semaphorin-like activity increases in the presence of the anti-Plexin-A1 agonist antibody of the present invention, compared to that in the absence of the agonist antibody, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, 95% or more, 100% or more, 200% or more, 300% or more, 400% or more, 500% or more, 600% or more, 700% or more, 800% or more, 900% or more, or 1000% or more.

The recitation “prevents or attenuates” the class 3 semaphorin-like activity means that the class 3 semaphorin-like activity is reduced in the presence of the anti-Plexin-A1 antagonist antibody, compared to that in the absence of the antagonist antibody, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

Cell-Contracting Activity and Neuronal Outgrowth Inhibitory Activity

Sema3A exhibits contracting activities for various cells, for example, by retracting neuronal growth cones of neurons to suppress axonal extension, or by inducing dendritic cell contraction during the process in which dendritic cells pass through microlymphatic vessels, thereby controlling migration of dendritic cells. Sema3A thus controls diverse biological reactions including neuronal circuit formation and immunoreactions.

Any methods known to those skilled in the art can be used as appropriate for measuring cell contraction, and examples of such methods include, although not limited to, a method that involves direct image analysis of cell morphology, and a method that involves measuring changes in cell morphology or adhesiveness as electrical impedance, using an apparatus such as xCELLigence (registered trademark).

Method that Involves Direct Image Analysis of Cell Morphology

Cells such as various tumor cells, endothelial cells including HUVEC, dorsal root ganglion (DRG) neurons, and dendritic cells are seeded into 96-well cell culture plates, and cultured for several hours to 1 day to induce cell adhesion. This is followed by the addition of Sema3A, and the cells are further cultured in a 37° C., CO₂ 5% incubator for about 30 minutes to several hours. In this case, wells without the addition of Sema3A are provided as a control. Then, images of cell morphology are taken by microscopic observation or using a cell image analyzer for high-content screening such as ArrayScan (registered trademark), and changes in cell morphology are quantified by means of image analysis software (e.g., Cellomics-vHCSTM:Scan).

As an example of an index used for quantifying changes in cell morphology, an index denoted as the “%High Object Convex Hull Area ratio” may be used, for example. This involves computing the proportion of cells for which the computed value of the ratio of the cell area to the convex hull area exceeds a certain threshold, and comparing this value between the cases with and without the addition of Sema3A to measure the cell contraction-inducing activity of Sema3A. The cell contraction means that the above-described value is reduced with the addition of Sema3A, compared to that without the addition of Sema3A, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

The recitation “the agonist antibody of the present invention has a contraction-promoting activity” means that the above-described value as measured using the above-described method is reduced in the presence of the antibody, compared to that in the absence of the antibody, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

Examples of other indices used for quantifying changes in cell morphology include an index obtained by quantifying neurite outgrowth as the average neurite outgrowth/neuron/well through the use of the neurite outgrowth application of image analysis software (e.g., Cellomics-vHCSTM:Scan). The cell contraction means that the above-described value is reduced with the addition of Sema3A, compared to that without the addition of Sema3A, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

The recitation “the agonist antibody of the present invention has a contraction-promoting activity” means that the above-described value as measured using the above-described method is reduced in the presence of the antibody, compared to that in the absence of the antibody, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

Additionally, a method can also be used that involves computing the area of cells from taken images, and determining cells for which the cell area has decreased below a certain threshold to be retracted cells.

Method that Involves Measuring Changes in Cell Morphology and/or Adhesiveness as Electrical Impedance

Cells such as various tumor cells, endothelial cells including HUVEC, dorsal root ganglion (DRG) neurons, and dendritic cells are seeded into the tissue culture E-Plate having electrodes integrated into the bottom of the wells, and cultured for several hours to 1 day to induce cell adhesion. This is followed by the addition of Sema3A, and the cells are further cultured in a 37° C., CO₂ 5% incubator for about several minutes to several hours. In this case, wells without the addition of Sema3A are provided as a control. Changes in cell morphology and/or adhesiveness are detected as electrical impedance, using CELLigence (registered trademark). This electrical impedance is detected using RTCA software (registered trademark), which is analytical software of xCELLigence (registered trademark), and created as a unitless parameter referred to as Cell Index (CI). Alternatively, a unitless parameter referred to as Normalized Cell Index is computed from a relative change in CI with respect to the current cell status. This Normalized CI value is compared between the cases with and without the addition of Sema3A to measure the cell contraction-inducing activity of Sema3A. The cell contraction means that the CI value is reduced with the addition of Sema3A, compared to that without the addition of Sema3A, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

The recitation that “the agonist antibody of the present invention has a contraction-promoting activity” means that the above-described value as measured using the above-described method is reduced in the presence of the antibody, compared to that in the absence of the antibody, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

Activity to Promote Migration of Dendritic Cells to Draining Lymph Node

Sema3A exhibits an actomyosin contraction-inducing activity by acting upon a heteroreceptor complex between Plexin-A1 and Neuropilin-1 on dendritic cells, and controls the passage of dendritic cells through intercellular spaces of microlymphatic vessels by inducing changes in cell morphology.

Any methods known to those skilled in the art can be used as appropriate for measuring the activity, and examples of such methods include, although not limited to, a method that involves measuring the activity through the use of an in vitro cell migration assay using the Boyden chamber.

Specifically, the Transwell (Corning) is placed in a 24-well plate containing 0.6 mL of 0.1% BSA in RPMI1640 containing chemokines such as CCL21 and CXCL12. Dendritic cells are added to the upper chamber of the Transwell and incubated at 37° C. for 1 to 3 hours. Then, the number of cells in the lower chamber is counted. For a transendothelial cell migration assay, lymphatic endothelial cells or vascular endothelial cells are deposited on the upper chamber. Briefly, SVEC4-10 or HMVEC-dLy cells are seeded in an upper or lower part of a Transwell insert coated with 2 μg/mL of fibronectin. After 1 to 2 days of culturing, a transendothelial cell migration assay is performed in accordance with the same method as that of the cell migration assay described above. The cell migration-promoting activity of Sema3A is measured as follows: In these assays, Sema3A is added with dendritic cells into the upper chamber of the Transwell, and comparing the measured number of dendritic cells migrated to the lower chamber with that in wells without the addition of Sema3A.

The activity to promote migration of dendritic cells to draining lymph node means that the number of dendritic cells migrated to the lower chamber increases in wells to which Sema3A was added, compared to that in wells to which Sema3A was not added, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

Osteoclast Differentiation-Suppressing Activity and Osteoblast Differentiation-Promoting Activity

Sema3A has been reported to exhibit a bone-protecting activity by exerting suppressive action upon osteoclast differentiation, and simultaneously exerting promotional action upon osteoblast activation, through receptors expressed by osteoclasts and osteoblasts.

Any methods known to those skilled in the art can be used as appropriate for measuring the osteoclast differentiation-suppressing activity or osteoblast differentiation-promoting activity, and examples of such methods include, although not limited to, the following methods.

Osteoclast Differentiation-Suppressing Activity

While a variety of methods are available for measuring the activity, the activity may be evaluated by, for example, tartrate-resistant acid phosphatase (TRAP) staining. Specifically, bone marrow cells are cultured in M-CSF-containing a-MEM medium for 48 hours or longer to prepare bone marrow monocyte/macrophage precursor cells. The medium is replaced with medium supplemented with RANKL, and the culture is continued for several days. For the evaluation of Sema3A, the medium is replaced with medium supplemented with Sema3A, and RANKL is added after 10 to 12 hours and the culture is continued for several days. The medium is replaced at an interval of several days, and after osteoclast formation is confirmed, TRAP staining and nuclear staining are performed. The osteoclast differentiation-suppressing activity of Sema3A is measured as follows: A stained image of cells to which Sema3A was added is acquired using a microscope or a cell image analyzer for high-content screening such as ArrayScan (registered trademark), and this stained image is compared with that of cells to which Sema3A was not added. Specifically, numbers of TRAP-positive cells or numbers of TRAP-positive multinucleated cells per well are counted and compared.

The osteoclast differentiation-suppressing activity means that the number of TRAP-positive cells or the number of TRAP-positive multinucleated cells is reduced in wells to which Sema3A was added, compared to that in wells to which Sema3A was not added, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, or 95% or more.

Osteoblast-Activating Activity

While a variety of methods are available for measuring the activity, the activity can be evaluated by, for example, alkaline phosphatase (ALP) staining or ALP activity measurement, or calcification detection. Specifically, calvarial cells or MC3T3-E1 cells are seeded into collagen-coated plates, and cultured in a-MEM medium containing ascorbic acid and β-glycerophosphoric acid. For the evaluation of Sema3A, Sema3A is added to the medium, and the cells are cultured. The medium is replaced at an interval of several days, and, after the completion of culture, ALP staining is performed, and then images are taken with a microscope, or the ALP activity is measured using absorptiometry. For calcification detection, Alizarin Red staining is performed. The osteoblast-activating effect of Sema3A is evaluated as follows: A stained image of cells to which Sema3A was added is acquired with a microscope, and this stained image is compared with that of cells to which Sema3A was not added. Specifically, images of stained cells are taken with a microscope, and the presence or absence of the activity is determined by visually comparing intensities of ALP staining or Alizarin Red staining.

The osteoblast-activating activity means that the absorbance of ALP activity or the intensity of Alizarin Red staining increases in wells to which Sema3A was added, compared to that in wells to which Sema3A was not added, preferably by 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 50% or more, 75% or more, 80% or more, 90% or more, 95% or more, 100% or more, 200% or more, 300% or more, 400% or more, 500% or more, 600% or more, 700% or more, 800% or more, 900% or more, or 1000% or more.

Antibody

The term “antibody” is used in the broadest sense, and may refer to any of monoclonal antibodies, polyclonal antibodies, dimers, multimers, multi-specific antibodies (e.g., bispecific antibody), antibody derivatives, and modified antibodies (Miller K et al., J Immunol., 2003, 170(9), 4854-61), as long as they exhibit desired biological activities. The antibody may be murine, human, humanized, or chimeric, or may be derived from other species. The antibody disclosed herein may be any type (e.g., IgG, IgE, IgM, IgD, and IgA) or class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass of immunoglobulin molecule. The immunoglobulin may be derived from any species (e.g., humans, mice, or rabbits). Note that the terms “antibody” and “immunoglobulin” are interchangeably used in a broad sense.

An “antibody derivative” includes a portion of the antibody, preferably a variable domain of the antibody or at least an antigen binding region of the antibody. Antibody derivatives include, although not limited to, Fab, Fab′, F(ab′)2 or Fv fragments, linear antibodies, single-chain antibodies (scFv), sc(Fv)_(2,) Fab_(3,) domain antibodies (dAb) (WO 2004/058821 and WO 2003/002609), diabodies, triabodies, tetrabodies, minibodies, and multi-specific antibodies formed from antibody derivatives. As used herein, the term “Fv” refers to a minimal antibody derivative, and includes a complete antigen recognition region and antigen binding region. Furthermore, the antibody derivative may be an IgG antibody fused with Fc. Reference may be made to, for example, the specification of U.S. Pat. No. 5,641,870, EXAMPLE 2; Zapata G et al., Protein Eng., 1995, 8(10), 1057-1062; Olafsen T et al., Protein Eng. Design & Sel., 2004, 17(4):315-323; Holliger P et al., Nat. Biotechnol., 2005, 23(9); 1126-36; Fischer N et al., Pathobiology, 2007, 74(1): 3-14; Shen J et al., J. Immunol Methods., 2007, 318, 65-74; and Wu et al., Nat. Biotechnol., 2007, 25(11), 1290-7.

The term “bispecific” antibody refers to an antibody having variable regions that recognize different epitopes in the same antibody molecule. The bispecific antibody may be an antibody that recognizes two or more different antigens, or may be an antibody that recognizes two or more different epitopes on the same antigen.

An IgG-type bispecific antibody can be secreted by a hybrid hybridoma (quadroma) produced by fusing two types of hybridomas that produce IgG antibodies (Milstein C et al., Nature, 1983, 305: 537-540). An IgG-type bispecific antibody can also be secreted by introducing genes of L chains and H chains constituting two IgGs of interest, i.e., a total of four types of genes, into cells for co-expression.

In this case, if a suitable amino acid substitution is introduced into the CH3 region of an H chain, IgGs having a heterologous combination of H chains can be preferentially secreted (Ridgway JB et al., Protein Engineering, 1996, 9: 617-621; Merchant A M et al., Nature Biotechnology, 1998, 16: 677-681; WO2006/106905; and Davis J H et al., Protein Eng. Des. Sel., 2010, 4: 195-202).

Regarding L chains, L chain variable regions are less diverse than H chain variable regions, and hence, a common L chain that may confer a binding capacity to both H chains can be obtained. Efficient expression of a bispecific IgG is achieved by introducing the genes of the common L chain and both H chains into cells for expression of IgGs.

As used herein, the term “common L chain” refers to an L chain that can associate with two or more different H chains, and exhibit binding capacities to the respective antigens. The term “different H chains” preferably refers to H chains of antibodies directed against different antigens, but is not limited thereto, and also refers to H chains that differ in amino acid sequence from each other. The common L chain can be acquired in accordance with the method described in WO 2006/109592, for example.

A bispecific antibody can also be prepared by chemically crosslinking Fab's. Instead of chemical crosslinking, a leucine zipper derived from Fos, Jun, or the like can also be used, and this method is similarly applicable to scFv, Fv, and the like, without being limited to Fab′.

Additionally, bispecific antibodies are also known including IgG-scFv (Protein Eng. Des. Sel., 2010, Apr; 23(4): 221-8), sc(Fv)2 such as BiTEs (Drug Discov. Today, 2005, Sep 15; 10(18): 1237-44), DVD-Ig (Nat. Biotechnol., 2007, Nov; 25(11): 1290-7. Epub 2007 Oct 14, MAbs, 2009, July; 1(4): 339-47. Epub 2009 Jul 10, and IDrugs, 2010, 13: 698-700), two-in-one antibodies (Science, 2009, Mar 20; 323(5921): 1610-4, and Immunotherapy, 2009, Sep; 1(5): 749-51), Tri-Fab, tandem scFv, and diabodies (MAbs, 2009, November; 1(6):539-547). Furthermore, bispecific antibodies can be efficiently prepared by preferentially secreting a heterologous combination of Fc fragments, using molecular forms such as scFv-Fc and scaffold-Fc (Ridgway J B et al., Protein Engineering, 1996, 9: 617-621, Merchant AM et al., Nature Biotechnology, 1998, 16: 677-681, WO2006/106905, and Davis JH et al., Protein Eng. Des. Sel., 2010, 4: 195-202).

The “antibody which cross-reacts”, which is also referred to as a cross-reacting antibody, cross-reactive antibody, or cross-reaction antibody, refers to an antibody that recognizes an identical or similar epitope on a plurality of antigens. As used herein, the plurality of antigens may be, for example, antigens of the same or different species.

Examples of modified antibodies include antibodies conjugated to various molecules such as polyethylene glycol (PEG). The substance to be conjugated with a modified antibody of the present invention is not limited. Such a modified antibody can be obtained by chemically modifying a produced antibody. Such methods have already been established in the art.

Examples of antigen binding regions include antibodies, scaffold molecules (antibody-like molecules), sites necessary for binding with antigens such as peptides, and fragments including such sites. Scaffold molecules are molecules that exhibit their functions by binding to target molecules, and any conformationally stable polypeptides capable of binding to at least one target antigen can be used as scaffold molecules. Examples of such polypeptides include antibody variable regions, fibronectin (WO 2002/032925), protein A domains (WO 1995/001937), LDL receptor A domains (WO 2004/044011 and WO 2005/040229), ankyrin (WO 2002/020565), and the molecules described in Nygren et al. (Current Opinion in Structural Biology, 7: 463-469 (1997), and Journal of Immunol. Methods, 290: 3-28 (2004)), Binz et al. (Nature Biotech., 23: 1257-1266 (2005)), and Hosse et al. (Protein Science, 15: 14-27 (2006)). Additionally, peptide molecules capable of binding to target antigens can be used, as described in Curr. Opin. Mol. Ther., 2010 August; 12(4): 487-95; and Drugs, 2008; 68(7): 901-12.

The antibody of the present invention is preferably a recombinant antibody produced using a gene recombination technique. A recombinant antibody can be obtained by cloning DNA encoding the antibody from hybridomas or antibody-producing cells such as antibody-producing sensitized lymphocytes, incorporating the cloned DNA into a vector, and introducing the vector into a host (host cells) to produce the antibody.

The antibody of the present invention may be from a non-limiting species, for example, a human antibody, a mouse antibody, or a rat antibody. The antibody of the present invention may also be a genetically engineered antibody such as a chimeric antibody or a humanized antibody.

Genetically engineered antibodies can be produced using existing methods. Specifically, a chimeric antibody, for example, is an antibody containing H chain and L chin variable regions of an antibody from immunized animals, as well as H chain and L chain constant regions of a human antibody. The chimeric antibody can be obtained by ligating DNA encoding the variable regions of the antibody from immunized animals to DNA encoding the constant regions of the human antibody, incorporating the resulting product into an expression vector, and introducing the vector into a host to produce the antibody.

Methods for acquiring human antibodies are already known, and a human antibody of interest can be acquired by, for example, immunizing a transgenic animal having the entire repertoire of human antibody genes with an antigen of interest (see WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).

Furthermore, a human antibody can be produced by a hybridoma-based method.

Human myeloma and mouse-human heterologous cell lines for the production of human monoclonal antibodies are usable (see Kozbor J., Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991)). Human antibodies produced via a human B cell hybridoma technique are also known (see Li et al., Proc.Natl. Acad. Sci. USA, 103: 3557-3562 (2006)). A human hybridoma technique (trioma technique) is also usable (see Vollmers and Brandlein, Histology and Histopathology, 20(3): 927-937 (2005); and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3): 185-91 (2005)).

A human antibody can also be produced by isolating an Fv clone variable domain sequence selected from a human phage display library. Such a variable domain sequence may be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries will be described hereinafter. Note that these techniques are also applicable to antibodies other than human antibodies.

Many antibody libraries are already known, and methods for preparing such antibody libraries are also known; therefore, those skilled in the art can acquire an antibody library, as appropriate. For phage libraries, for example, reference may be made to documents such as Clackson et al., Nature, 1991, 352: 624-8, Marks et al., J. Mol. Biol., 1991, 222: 581-97, Waterhouses et al., Nucleic Acids Res., 1993, 21: 2265-6, Griffiths et al., EMBO J., 1994, 13: 324.0-60, Vaughan et al., Nature Biotechnology, 1996, 14: 309-14, and WO 96/07754. Additionally, known methods such as a method for producing libraries using eukaryotic cells (WO 95/15393) and a ribosome display method can be used.

Libraries include, although not limited to, libraries known to those skilled in the art (Methods Mol. Biol., 2002; 178: 87-100; J. Immunol. Methods, 2004 June; 289(1-2): 65-80; and Expert Opin. Biol. Ther., 2007 May; 7(5): 763-79), i.e., human naive libraries, non-human animal and human immune libraries, semi-synthetic and synthetic libraries. Examples of methods, however, are not particularly limited thereto.

Furthermore, a technique for acquiring human antibodies through panning by using human antibody libraries is known. For example, human antibody variable regions as single-chain antibodies (scFvs) may be expressed on the phage surface in accordance with a phage display method, and phages bound to the antigen may be selected. Through analysis of the genes of the selected phages, DNA sequences encoding the human antibody variable regions bound to the antigen can be determined. Once the DNA sequences of scFvs bound to the antigen are known, suitable expression vectors can be prepared on the basis of these sequences to acquire human antibodies. Such methods are already well known, and reference can be made to WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, and WO 95/15388.

Antibodies or antibody fragments isolated from human antibody libraries are regarded herein as human antibodies or human antibody fragments.

A humanized antibody is an engineered antibody also referred to as a reshaped human antibody. A humanized antibody is constructed by grafting the CDRs of an antibody derived from an immunized animal into the complementarity determining regions of a human antibody. Common gene recombination techniques therefor are also known (see European Patent Application Publication No. 239,400, WO 96/02576, Sato K et al, Cancer Research, 1993, 53: 851-856, and WO 99/51743).

Specific preferred embodiments of the agonist antibody of the present invention include antibodies comprising the following amino acid sequences described in the Examples below:

(a) An antibody comprising amino acid sequences of H chain CDRs 1, 2 and 3 as set forth in SEQ ID NOS: 23, 24 and 25 (H chain CDRs of hPANL#240) and amino acid sequences of L chain CDRs 1, 2 and 3 as set forth in SEQ ID NOS: 26, 27 and 28 (L chain CDRs of hPANL#240).

(b) An antibody comprising amino acid sequences of H chain CDRs 1, 2 and 3 as set forth in SEQ ID NOS: 29, 30 and 31 (H chain CDRs of 359B-2-2-3-6) and amino acid sequences of L chain CDRs 1, 2 and 3 as set forth in SEQ ID NOS: 32, 33 and 34 (L chain CDRs of 359B-2-2-3-6).

Specific preferred embodiments of the agonist antibody of the present invention further include antibodies comprising the following amino acid sequences described in the Examples below:

(a) An antibody comprising an amino acid sequence of an H chain variable region as set forth in SEQ ID NO: 21 (H chain variable region of hPANL#240) and an amino acid sequence of an L chain variable region as set forth in SEQ ID NO: 22 (L chain variable region of hPANL#240).

(b) An antibody comprising an amino acid sequence of an H chain variable region as set forth in SEQ ID NO: 35 (H chain variable region of 359B-2-2-3-6) and an amino acid sequence of an L chain variable region as set forth in SEQ ID NO: 36 (L chain variable region of 359B-2-2-3-6).

Specific preferred embodiments of the agonist antibody of the present invention further include antibodies comprising the following amino acid sequences described in the Examples below:

(a) An antibody comprising an amino acid sequence of an H chain as set forth in SEQ ID NO: 9 (H chain of hPANL#240) and an amino acid sequence of an L chain as set forth in SEQ ID NO: 10 (L chain of hPANL#240).

(b) An antibody comprising an amino acid sequence of an H chain as set forth in SEQ ID NO: 11 (H chain of 359B-2-2-3-6) and an amino acid sequence of an L chain as set forth in SEQ ID NO: 12 (L chain of 359B-2-2-3-6).

One embodiment of the present invention provides nucleic acid encoding H chain and L chain CDRs, variable regions, or the full length of the antibody sequence of hPANL#240 or 359B-2-2-3-6.

Another embodiment provides a vector incorporating the nucleic acid.

Still another embodiment provides host cells transformed with the vector.

Still another embodiment provides a method for producing the above-described antibodies by culturing the above-described cells.

Still another embodiment provides antibodies produced by the above-described method.

One embodiment of the present invention provides an anti-Plexin-A1 antibody that competes with hPANL#240 or 359B-2-2-3-6 for binding to Plexin-A1. Preferred is an anti-Plexin-A1 antibody that competes with hPANL#240 or 359B-2-2-3-6 for binding to the sema domain of Plexin-A1. More preferred is an anti-Plexin-A1 antibody that competes with hPANL#240 or 359B-2-2-3-6 for binding to residues 461-514 of SEQ ID NO: 3 in the sema domain of human Plexin-A1 , or for binding to residues 459-512 of SEQ ID NO: 52 in the same domain of mouse Plexin-A1.

The present invention also provides an antibody that binds to an epitope that overlaps with that bound by the agonist antibody of the present invention. It can be confirmed whether one antibody recognizes an epitope that overlaps with that of another antibody, by competition of these antibodies for the epitope. Competition between antibodies can be evaluated by a competition binding assay, and examples of such means include biomolecular interaction analysis, including enzyme-linked immunosorbent assay (ELISA), fluorescence resonance energy transfer (FRET) assay, fluorometric microvolume assay technology (FMAT (registered trademark)), electrochemiluminescence (ECL), AlphaScreen (chemically amplified luminescence proximity homogeneous assay), radioimmunoassay (RIA), scintillation proximity assay (SPA), surface acoustic wave (SAW), microscale thermophoresis (NanoTemper Technologies), quartz crystal microbalance (QCM), Octet (from ForteBIO), and surface plasmon resonance; and kinetic exclusion assay (KinExA (registered trademark)). The amount of the antibody bound to the antigen is indirectly correlated with the binding capacity of a competing antibody candidate (test antibody) that competes for binding to the overlapping epitope. That is, as the amount or affinity of the test antibody for the overlapping epitope increases, the amount of binding of the antibody to the antigen decreases, and the amount of binding of the test antibody to the antigen increases. Specifically, the suitably labeled antibody and the test antibody are simultaneously added to the antigen, and the bound antibody is detected using the label. The amount of the antibody bound to the antigen can be readily measured by pre-labeling the antibody. For this labeling, any labeling method suitable for the technique may be selected without particular limitation. Examples of labeling methods include fluorescent labeling, radiolabeling, and enzyme labeling. For example, the fluorescently labeled antibody and the unlabeled antibody or test antibody are simultaneously added to Plexin-A1-immobilized beads, and the labeled antibody is detected using the fluorometric microvolume assay technology. Furthermore, through the use of biomolecular interaction analysis or kinetic exclusion assay, competition can be evaluated without the need to use the labeled antibody. The overlapping epitope includes not only a case where the epitopes of two antibodies are completely identical, but also a case where the epitopes are partially identical. The antibody that binds to the overlapping epitope may also be referred to herein as the antibody that binds to a competing epitope, or the competing antibody.

As used herein, the “antibody that binds to the overlapping epitope”, “competing antibody”, or “antibody that binds to a competing epitope” includes, for example, cases where the antibody and the test antibody do not substantially simultaneously bind to Plexin-A1. As used herein, the recitation “do not substantially simultaneously bind” refers to 60% or less, typically 50% or less, preferably 30% or less, and particularly preferably 15% or less of the binding activity of the antibody for Plexin-A1. Note that analysis of the epitope recognized by the antibody can be performed using a method known to those skilled in the art, for example, Western blotting.

A multi-specific antigen binding molecule having an antigen binding site of an antibody that binds to an epitope bound by the above-described agonist antibody or an epitope that overlaps with the epitope is capable of promoting a class 3 semaphorin-like activity, which is, for example, cell contraction. Furthermore, in the antigen binding site of the antibody that binds to the epitope that overlaps with the epitope bound by the above-described antibody, one or more amino acids can be modified to obtain an improved class 3 semaphorin-like activity.

As used herein, the term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., a population of antibodies in which the individual antibodies constituting the population are homogeneous except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, and are typically directed against a single antigenic site. Furthermore, in contrast to conventional polyclonal antibody preparations that typically contain different antibodies directed against different antigenic determinants (epitopes), a monoclonal antibody is directed against a single antigenic determinant on the antigen. In addition to their specificities, monoclonal antibodies are advantageous in that they are synthesized by, for example, hybridoma culture that does not include other antibodies. Note that the modifier “monoclonal” suggests the characteristics of the antibody obtained from a population of substantially homogeneous antibodies, and does not require the antibody to be produced by any specific method. For example, the monoclonal antibody used in the present invention may be produced by, for example, the hybridoma method (e.g., Kohler and Milstein, Nature, 256: 495 (1975)) or the recombination method (e.g., U.S. Pat. No. 4,816,567). The monoclonal antibody used in the present invention may also be isolated from phage antibody libraries (e.g., Clackson et al., Nature, 352:624-628 (1991); Marks et al., J. Mol. Biol., 222:581-597 (1991)).

The antibody of the present invention can be produced by a method known to those skilled in the art. Specifically, DNA encoding an antibody of interest is incorporated into an expression vector. In this case, the DNA is incorporated into the expression vector so as to be expressed under the control of an expression-controlled region, for example, an enhancer or promoter. Then, host cells are transformed with this expression vector for expression of the antibody. In this case, a suitable combination of a host and an expression vector may be used.

Examples of vectors include M13-based vectors, pUC-based vectors, pBR322, pBluescript, and pCR-Script. For the purpose of cDNA subcloning or processing, pGEM-T, pDIRECT, and pT7, for example, can be used besides the above-described vectors.

For the purpose of antibody production, expression vectors are particularly useful. For example, when the host is E. coli such as JM109, DH5α, HB101, or XL1-Blue, the expression vector to be used essentially has a promoter that can be efficiently expressed in E. coli, for example, lacZ promoter (Ward et al., Nature, (1989) 341, 544-546; FASEB J., (1992) 6, 2422-2427), araB promoter (Better et al., Science, (1988) 240, 1041-1043), or T7 promoter. Examples of such vectors include, in addition to the above-described vectors, pGEX-5X-1 (from Pharmacia), “QIAexpress system” (from QIAGEN), pEGFP, and pET (in this case, the host is preferably BL21 expressing T7 RNA polymerase).

The vector may also contain a signal sequence for polypeptide secretion. For production in the periplasm of E. coli, the pelB signal sequence (Lei, S. P. et al., J. Bacteriol., (1987) 169, 4397), for example, may be used as the signal sequence for polypeptide secretion. The vector can be introduced into the host cells using, for example, the calcium chloride method or electroporation.

In addition to the E. coli expression vectors, examples of vectors for producing the antibody of the present invention include mammalian expression vectors (e.g., pcDNA3 (from Invitrogen), pEGF-BOS (Nucleic Acids. Res., 1990, 18(17), p5322), pEF, and pCDM8), insect cell expression vectors (e.g., “Bac-to-BAC baculovairus expression system” (from GIBCO BRL) and pBacPAK8), plant expression vectors (e.g., pMH1 and pMH2), animal virus expression vectors (e.g., pHSV, pMV, and pAdexLcw), retroviral expression vectors (e.g., pZlPneo), yeast expression vectors (e.g., “Pichia Expression Kit” (from Invitrogen), pNV11, and SP-Q01), and Bacillus subtilis expression vectors (e.g., pPL608 and pKTH50).

For the purpose of expression in animal cells such as CHO cells, COS cells, and NIH3T3 cells, the expression vector to be used essentially has a promoter required for intracellular expression, for example, SV40 promoter (Mulligan et al., Nature, (1979) 277, 108), MMTV-LTR promoter, EF1α promoter (Mizushima et al., Nucleic Acids Res., (1990) 18, 5322), CAG promoter (Gene, (1991) 108, 193), or CMV promoter, and the expression vector preferably also has a gene for selection of transformed cells. Examples of genes for selection of transformed cells include drug resistance genes that can be distinguished by drugs (e.g., neomycin and G418). Examples of vectors having such characteristics include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.

Furthermore, for the purpose of stable gene expression and amplification of gene copy number in cells, nucleic acid synthesis pathway-deficient CHO cells may be transfected with a vector (e.g., pCHOI) having the DHFR gene complementary thereto, and the gene may be amplified using methotrexate (MTX). For the purpose of transient gene expression, COS cells having an SV40 T antigen-expressing gene on the chromosome may be transformed with a vector (e.g., pcD) having an SV40 replication origin. A replication origin derived from polyomavirus, adenovirus, or bovine papillomavirus (BPV), for example, may also be used. Furthermore, for amplification of gene copy number in a host cell system, the expression vector may contain, as a selection marker, aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E. coli xanthine guanine phosphoribosyl transferase (Ecogpt) gene, or dihydrofolate reductase (dhfr) gene, for example.

The antibody of the present invention thus obtained can be isolated from inside or outside the host cells (e.g., medium), and purified as a substantially pure, homogeneous antibody. There are no limitations on methods for separation and purification of the antibody, and those that are commonly used for antibody purification may be used. For example, the antibody can be separated and purified by suitably selecting and combining methods including chromatography columns, filters, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, and recrystallization.

Examples of chromatography include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reversed phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). These types of chromatography can be performed using liquid phase chromatography, for example, HPLC or FPLC. Examples of columns used for affinity chromatography include Protein A columns and Protein G columns. Examples of columns using Protein A include Hyper D, POROS, and Sepharose FF (GE Amersham Biosciences). The present invention also includes antibodies that are highly purified using these purification methods.

The obtained antibody can be purified to homogeneity. For antibody separation and purification, any separation and purification methods commonly used for proteins may be used. For example, the antibody can be separated and purified by suitably selecting and combining methods including, although not limited to, chromatography columns for affinity chromatography and the like, filters, ultrafiltration, salting out, dialysis, SDS-polyacrylamide gel electrophoresis, and isoelectric focusing (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988). Examples of columns used for affinity chromatography include Protein A columns and Protein G columns.

One embodiment of the present invention provides a method for producing an anti-Plexin-A1 agonist antibody by using, as an antigen, a peptide consisting of residues 461-514 of SEQ ID NO: 3 in the sema domain of human Plexin-A1 or a peptide consisting of residues 459-512 of SEQ ID NO: 52 in the same domain of mouse Plexin-A1. Another embodiment of the present invention provides an anti-Plexin-A1 agonist antibody produced by the above-described method. The anti-Plexin-A1 agonist antibody can be produced using the methods already described herein or methods well known to those skilled in the art.

Use of Anti-Plexin-A1 Agonist Antibody

The anti-Plexin-A1 agonist antibody of the present invention, which exhibits a class 3 semaphorin-like activity by binding to Plexin-A1 , is useful for treating and preventing diseases associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, preferably Sema3A. The anti-Plexin-A1 agonist antibody of the present invention is particularly useful for treating and preventing various diseases such as autoimmune diseases including pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus, inflammatory diseases, and tumors.

Pharmaceutical Composition

The present invention also provides a pharmaceutical composition containing the anti-Plexin-A1 agonist antibody of the present invention. As described above, the anti-Plexin-A1 agonist antibody of the present invention is useful as a prophylactic/therapeutic agent for diseases associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, preferably Sema3A (e.g., autoimmune diseases including pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus, inflammatory diseases, and tumors). Furthermore, when the anti-Plexin-A1 agonist antibody of the present invention is used as a pharmaceutical composition, it is preferably a human antibody or humanized antibody in view of antigenicity in humans, for example.

The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier. Examples of pharmaceutically acceptable carriers include sterilized water, saline solution, stabilizers, excipients, antioxidants (e.g., ascorbic acid), buffers (e.g., phosphoric acid, citric acid, and other organic acids), preservatives, surfactants (e.g., PEG and Tween), chelating agents (e.g., EDTA), and binders. The pharmaceutical composition of the present invention may additionally contain proteins such as low-molecular-weight polypeptides, serum albumin, gelatin, and immunoglobulins, amino acids such as glycine, glutamine, asparagine, arginine, and lysine, carbohydrates or saccharides such as polysaccharides and monosaccharides, and sugar alcohols such as mannitol and sorbitol. When the pharmaceutical composition of the present invention is formulated into injectable aqueous solutions, examples of such aqueous solutions include saline solution and isotonic solutions containing glucose or other adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride. These aqueous solutions may be used in combination with suitable solubilizing agents, such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol and PEG), and nonionic surfactants (e.g., polysorbate 80 and HCO-50).

The pharmaceutical composition of the present invention can be encapsulated in microcapsules (microcapsules such as hydroxymethylcellulose, gelatin, and poly[methylmethacrylate]), or can be formulated into a colloidal drug delivery system (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), as required (see, for example, “Remington's Pharmaceutical Science 16th edition”, Oslo Ed., 1980). Methods for the preparation of sustained-release drugs are also known, and can be applied to the present invention (Langer et al., J. Biomed. Mater. Res., 1981, 15: 167-277; Langer, Chem. Tech., 1982, 12: 98-105; US3773919; EP58481; Sidman et al., Biopolymers, 1983, 22: 547-556; and EP133988).

The pharmaceutical composition of the present invention can be administered to patients either orally or parenterally, preferably parenterally. Examples of forms (dosage forms) of the pharmaceutical composition of the present invention include, although not particularly limited to, injection dosage forms, nasal dosage forms, pulmonary dosage forms, percutaneous dosage forms, lyophilized dosage forms, and solution dosage forms.

Lyophilization can be performed using methods well known to those skilled in the art (Pharm. Biotechnol., 2002, 13, 109-33, Int. J. Pharm., 2000, 203(1-2), 1-60, and Pharm. Res., 1997, 14(8), 969-975). For example, lyophilization may be performed as follows: A suitable volume of the solution is dispensed into a container used for lyophilization such as a vial, and then lyophilized in a lyophilizer or freeze-dryer, or the solution is immersed in refrigerants such as acetone/dry ice and liquid nitrogen. Furthermore, the antibody preparation can be formulated into a highly concentrated solution preparation, using a method well known to those skilled in the art. For example, the membrane concentration method using a TFF membrane may be used, as described in J. Pharm. Sc., 2004, 93(6), 1390-1402.

An injectable dosage form can be systemically or locally administered by, for example, intravenous injection, intramuscular injection, intraperitoneal injection, or subcutaneous injection. The administration method can be selected as appropriate, according to the patient's age and symptoms. The dose can be selected from, for example, the range of 0.0001 to 1000 mg per kg body weight at one time. Alternatively, the dose can be selected from, for example, the range of 0.001 to 100000 mg/body per patient. However, the dose, administration method, and the like of the present invention are not limited to those described above.

A therapeutically and prophylactically effective amount of the anti-Plexin-A1 agonist antibody means an amount of the agonist that is effective for preventing, retarding, alleviating, or inhibiting symptoms or activity associated with a disease or disorder when the anti-Plexin-A1 agonist antibody is administered to a subject. The anti-Plexin-A1 agonist antibody may be administered in one or multiple doses, and may be given in combination with other pharmacological composition(s).

Kit

The present invention provides a kit for preventing and/or treating diseases associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, preferably Sema3A, which kit comprises at least the anti-Plexin-A1 agonist antibody or pharmaceutical composition of the present invention. In particular, the present invention provides a kit for preventing and/or treating autoimmune diseases including pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus, inflammatory diseases, and tumors, which kit comprises the anti-Plexin-A1 agonist antibody or pharmaceutical composition. Additionally, a syringe, an injection needle, a pharmacologically acceptable medium, an alcohol cotton cloth, plaster, instructions describing the method of use, and the like may be packaged with this kit.

The present invention also relates to use of the anti-Plexin-A1 agonist antibody or pharmaceutical composition of the present invention for the manufacture of a prophylactic and/or therapeutic agent for diseases associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, preferably Sema3A. In particular, the present invention relates to use of the anti-Plexin-A1 agonist antibody or pharmaceutical composition for the manufacture of a prophylactic and/or therapeutic agent for autoimmune diseases including pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus, inflammatory diseases, and tumors.

The present invention also relates to the anti-Plexin-A1 agonist antibody or pharmaceutical composition of the present invention for preventing and/or treating diseases associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, preferably Sema3A. In particular, the present invention relates to the anti-Plexin-A1 agonist antibody or pharmaceutical composition for preventing and/or treating autoimmune diseases including pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus, inflammatory diseases, and tumors.

The anti-Plexin-A1 agonist antibody or pharmaceutical composition of the present invention can be used in combination with other therapeutic agent(s). The anti-Plexin-A1 agonist antibody or pharmaceutical composition of the present invention may be administered simultaneously with the other therapeutic agent(s), or may be administered at a different time. Furthermore, the present invention may be implemented as a kit including a combination of the anti-Plexin-A1 agonist antibody or pharmaceutical composition of the present invention with the other therapeutic agent(s). When the anti-Plexin-A1 agonist antibody or pharmaceutical composition of the present invention is used in combination with the other therapeutic agent(s), the dose of each of these components may be set smaller, as desired, than that when any of these components is used alone.

As used herein, the embodiments expressed using the phrase “comprising . . . ”

includes embodiments expressed using the phrase “essentially consisting of . . . ” and embodiments expressed using the phrase “consisting of . . . ”.

The contents of all patent and reference documents explicitly cited herein shall be incorporated herein by reference in their entirety.

The present invention will be further illustrated using the following examples, which are not intended to limit the present invention.

EXAMPLES

The present invention will be hereinafter described in more detail with Examples, which are not intended to restrict the present invention.

Example 1 Preparation of Semaphorin 3A Recombinant Proteins

To prepare mouse semaphorin 3A protein, gene synthesis was performed on the basis of the sequence of NCBI Reference Sequence NP_033178.2, and arginine residues (positions 552, 555, 758, 760, and 761) in the protease recognition site were converted to alanine. The signal peptide (from the N-terminus to alanine at position 20) was replaced with artificial signal peptide HMM+38 (SEQ ID NO: 7), and His-tag sequence was inserted between the artificial signal peptide and asparagine at position 21, via a glutamic acid-aspartic acid-arginine spacer. Furthermore, serine at position 771 and valine at position 772 were deleted from the C-terminus. The amino acid sequence of the prepared mouse semaphorin 3A recombinant protein is shown in SEQ ID NO: 1. The prepared gene was incorporated into an expression vector and then introduced into FreeStyle293 cells from Invitrogen for expression, and the semaphorin 3A protein was purified from the culture supernatant by affinity purification using HisTrap excel (from GE Healthcare) and gel filtration chromatography.

To prepare human semaphorin 3A protein, gene synthesis was performed on the basis of the sequence of NCBI Reference Sequence NP_006071.1, and arginine residues (positions 552, 555, 757, 759, and 760) in the protease recognition site were converted to alanine. The signal peptide (from the N-terminus to alanine at position 20) was replaced with artificial signal peptide HMM+38 (SEQ ID NO: 7), and His-tag sequence was inserted between the artificial signal peptide and asparagine at position 21, via a glutamic acid-aspartic acid-arginine spacer. FLAG tag sequence (SEQ ID NO: 5) was further inserted at the C-terminus. The amino acid sequence of the prepared human semaphorin 3A recombinant protein is shown in SEQ ID NO: 2. The prepared gene was incorporated into an expression vector and then introduced into FreeStyle293 cells from Invitrogen for expression, and the semaphorin 3A protein was purified from the culture supernatant by affinity purification using HisTrap excel (from GE Healthcare) and gel filtration chromatography.

Example 2 Construction of Evaluation System for Mouse Semaphorin 3A Activity Using Mouse Dendritic Cell Contraction as Index

For evaluation of the action of the semaphorin 3A protein upon dendritic cell morphology contraction, a contraction assay using mouse bone marrow-derived dendritic cells was performed. The contraction assay was performed by the following method.

Mouse bone marrow-derived dendritic cells were prepared in accordance with the method of Inaba et al. (J Exp Med., 1992, 176(6): 1693-702). The mouse bone marrow-derived dendritic cells were suspended in RPMI1640 medium (from Nacalai Tesque) containing 10% FBS (from Moregate) and mouse GM-CSF (40 ng/mL; R&D systems), and the suspension was seeded into 96-well plates at 2×10⁴ cells/well and then cultured at 37° C. for 12 to 24 hours. The mouse semaphorin 3A protein was diluted to a suitable concentration with 10% FBS-containing RPMI1640 medium and added to the cell culture medium, and then the mixture was further incubated at 37° C. for 5 hours. The cells were fixed by treatment with PBS containing 4% paraformaldehyde, and cell membranes were permeabilized by treatment with PBS solution containing 0.1% Triton X-100. Then, the cells were treated with Alexa Fluor 488 (registered trademark)-labeled phalloidin and DAPI-containing PBS, thereby allowing actin polymers (F-actin) and nuclei to be stained, respectively. Cell morphology images were acquired using ArrayScan VTI (Thermo Fischer Scientific Inc.). These images were analyzed using the Morphology v4 protocol of the analytical software Cellomics-vHCSTM:Scan (Thermo Fischer Scientific Inc.), and changes in the morphology of dendritic cells were quantified using the index referred to as %High Object Convex Hull Area Ratio.

After 12 to 24 hours of culture, the dendritic cells exhibited a spindle-shaped cell morphology like an extended pseudopod; however, cell contraction was induced by further culturing the dendritic cells at 37° C. for 5 hours in the presence of mouse semaphorin 3A. FIG. 1 shows the results obtained by quantifying the cell contraction, using the above-described method.

Example 3 Preparation of Biotin-Labeled Human PlexinA1

The extracellular region of human Plexin-A1 (hPlexinA1), a single-pass transmembrane protein, was prepared as follows. From hPlexinA1 gene synthesized on the basis of the amino acid sequence of NCBI Reference Sequence NP_115618.3 (SEQ ID NO: 3), the portion after alanine at position 1245 predicted as the transmembrane region was removed, and the FLAG tag sequence (SEQ ID NO: 5) was added instead. Furthermore, the signal peptide from positions 1-26 (SEQ ID NO: 6) was replaced with artificial signal peptide HMM+38 (SEQ ID NO: 7). The prepared gene encoding hPlexinA1 (SEQ ID NO: 4) was incorporated into an animal cell expression vector, and then introduced into FreeStyle293 cells (Invitrogen) using 293Fectin (Invitrogen). At this time, the gene expressing EBNA1 (SEQ ID NO: 8) was simultaneously introduced for improved expression efficiency of the gene of interest. The cells transfected with the genes in accordance with the above-described procedure were cultured for 6 days at 37° C. and 8% CO_(2,) for secretion of the protein of interest in the culture supernatant.

The cell culture medium containing hPlexinA1 of interest was filtered through a 0.22 μm bottle-top filter to obtain culture supernatant. The culture supernatant was applied to anti-FLAG antibody M2 agarose (Sigma-Aldrich) equilibrated with D-PBS(−) (Wako Pure Chem), and then FLAG peptide in D-PBS was added, thereby allowing hPlexinA1 of interest to be eluted. Then, fractions containing hPlexinA1 were separated by gel filtration chromatography using D-PBS(−)-equilibrated Superdex 200 (GE Health Care).

Soluble hPlexinA1 prepared as described above was labeled with EZ-Link NHS-PEG4-Biotin (Thermo SCIENTIFIC), thereby preparing biotin-labeled hPlexinA1.

Example 4 Production of Soluble Mouse PlexinA1 Protein

Soluble mouse PlexinA1 protein was designed on the basis of the amino acid sequence of NCBI Reference Sequence NP_032907.1 (SEQ ID NO: 52) up to the extracellular domain. The signal peptide (from the N-terminus to isoleucine at position 24) was replaced with artificial signal peptide HMM+38 (SEQ ID NO: 7), and the FLAG tag sequence (SEQ ID NO: 5) was inserted at the C-terminus. The prepared amino acid sequence is shown in (SEQ ID NO: 16). The prepared gene was incorporated into an expression vector and then introduced into FreeStyle293 cells from Invitrogen for expression, and the soluble mouse PlexinA1 protein was purified from the culture supernatant by affinity purification using anti-FLAG M2 antibody affinity gel (Sigma-Aldrich) and gel filtration chromatography.

Example 5 Production of Anti-PlexinA1 Antibodies

Rabbits were immunized by the following method to prepare anti-mouse PlexinA1 antibodies.

Rabbits were immunized as follows: Initially, the rabbits were intradermally injected with a total of 100 μg of the soluble mouse PlexinA1 protein or soluble human PlexinA1 protein in complete Freund's adjuvant (CFA). Then, the rabbits received two or more booster immunizations with 50 μg per immunization of the soluble mouse PlexinA1 protein or soluble human PlexinA1 protein in incomplete Freund's adjuvant (IFA) at an interval of 1 week or longer.

Then, tissues were collected from the immunized rabbits, and a single cell suspension was prepared. Specifically, spleens and blood were obtained from individuals having elevated serum antibody titers, and peripheral mononuclear blood cells (PBMCs) were prepared from the blood. The peripheral mononuclear blood cells were prepared using the Ficoll method. The collected spleens were treated through a cell strainer (BD Falcon) to prepare the single cell suspension. The soluble PlexinA1 protein biotinylated with PBS(−) containing 0.5% BSA was added to the cells, and the cells were suspended. The cell suspension was incubated on ice for 30 minutes. The cells were washed with PBS(−) containing 0.5% BSA to remove biotinylated soluble PlexinA1 protein unbound to the cells. MACS streptavidin beads (Miltenyi Biotec) were added to the cells, and the cells were suspended and incubated on ice. After washing, MACS streptavidin bead-bound positive cell fractions were collected using the autoMACS Pro Separator. After the addition of anti-rabbit IgG-PE to the cells and incubation on ice, cell fractions of the cell suspension having high PE fluorescence values were collected using FACSAria (BD).

Collected B cells were cultured by the following method. The collected cells were seeded into 96-well plates to which activated rabbit T cell conditioned medium and EL4 cells (European Collection of Cell Cultures) were added. The activated rabbit T cell conditioned medium is a medium prepared by culturing thymocytes collected from rabbits in RPMI-1640 containing phytohaemagglutinin (Roche), phorbol 12-myristate 13-acetate (Sigma-Aldrich), and FBS. These cells were cultured for 5 to 12 days at 37° C. and 5% CO_(2,) and then a portion of the supernatant containing secreted antibodies was collected. The rabbit antibodies in the supernatant were evaluated for their binding activity to mouse PlexinA1.

Total RNA was collected from B cells whose binding activity was confirmed, and H chain and L chain antibody variable region genes were synthesized by RT-PCR. Antibody expression vectors were prepared by ligating these genes to the rabbit antibody H chain constant region sequence (SEQ ID NO: 17) and the rabbit antibody L chain constant region sequence (SEQ ID NO: 18). H chain and L chain expression vectors derived from the same well were mixed, FreeStyle293 (Invitrogen) cells were transfected with the genes, and the antibodies were purified from the culture supernatants.

Using the purified antibodies, antigen binding activities were evaluated by ELISA using a mouse PlexinA1-expressing cell line. The results are shown in FIG. 2. Anti-mouse PlexinA1 antibodies PXB361b, PXB693, and PXB727 were confirmed to be specifically bound to the mouse PlexinA1-expressing cell line in an antibody concentration-dependent manner. The amino acid sequences of the H chain and L chain variable regions of PXB361b are shown in SEQ ID NOS: 19 and 20, respectively, the amino acid sequences of the H chain and L chain variable regions of PXB693 are shown in SEQ ID NOS: 41 and 42, respectively, and the amino acid sequences of the H chain and L chain variable regions of PXB727 are shown in SEQ ID NOS: 43 and 44, respectively. Antagonistic activity of an anti-mouse PlexinA1 antibody was evaluated using the semaphorin 3A-dependent mouse bone marrow-derived dendritic cell contraction assay system described in Example 2. The results are shown in FIG. 3. The obtained anti-mouse PlexinA1 antibody PXB361b was observed to suppress dendritic cell contraction in a concentration-dependent manner, and was confirmed to exhibit an antagonistic activity to suppress semaphorin 3A signaling.

Example 6 Evaluation of Antibodies by Cell ELISA

The antibodies obtained above were subjected to cell ELISA by the following procedure. Initially, 384-well plates were prepared, and mouse PlexinA1-expressing Ba/F3 cells and Ba/F3 cells (see Example 11) were each captured onto the bottom of different wells. After washing each well of the plates with PBS, the prepared antibodies were added at 20 μL/well, and the mixture was allowed to stand at room temperature for 1 hour. Then, each well was washed with 0.05% Tween 20-PBS, HRP-labeled anti-rabbit IgG antibody (Betyl, A120-101P) diluted 10000 times with 2% FBS-PBS was added at 20 μL/well, and the mixture was allowed to stand at room temperature for 1 hour. After washing each well of the plates with 0.05% Tween 20-PBS, the substrate solution (ABTS peroxidase substrate system) was dispensed at 20 L/well to develop color for 1 hour at room temperature. Then, binding of the antibodies to mouse PlexinA1 was confirmed by measuring absorbance at 405 nm using SpectraMax from Molecular Devices, LLC.

Example 7 Production of Human Antibody Naive Library

Using Poly A RNA prepared from human PBMC or commercially available human Poly A RNA as a template, a gene library of antibody heavy chain variable regions and a gene library of antibody light chain variable regions were amplified by PCR.

The prepared gene library of antibody heavy chain variable regions and gene library of antibody light chain variable regions were combined, and then inserted into a phagemid vector to construct a human antibody phage display library displaying Fab domains consisting of human antibody sequences. For the construction method, reference was made to Methods Mol Biol., (2002) 178, 87-100. The above-described library was constructed using phage display library sequences in which a trypsin cleavage sequence was inserted into the linker region connecting the Fab and phage pIII protein of the phagemid, as well as between the N2 and CT domains of the helper phage pIII protein gene.

Example 8 Acquisition of Antibody Fragments That Bind to hPlexinA1 from Human Antibody Naive Library by Bead Panning

Phages were produced using E. coli carrying the constructed phagemids for phage display. A population of phages precipitated by adding 2.5M NaCl/10% PEG to the culture medium of E. coli used for the phage production was diluted with TBS to obtain phage library solution. This is followed by the addition of BSA and CaCl₂ to the phage library solution, thereby adjusting the phage library solution to final concentrations of 4% BSA and 1.2 mM calcium ions. For panning, reference was made to common panning methods using antigens immobilized onto magnetic beads (J. Immunol. Methods., (2008) 332 (1-2), 2-9; J. Immunol. Methods., (2001) 247 (1-2),191-203; Biotechnol. Prog., (2002) 18(2) 212-20; Mol. Cell Proteomics, (2003) 2 (2), 61-9). NeutrAvidin coated beads (Sera-Mag SpeedBeads NeutrAvidin-coated) or streptavidin coated beads (Dynabeads M-280-Streptavidin) were used as the magnetic beads.

Specifically, 250 pmol of the above-described biotin-labeled hPlexinA1 was added to the prepared phage library solution, thereby allowing the phage library solution to contact the antigen at room temperature for 60 minutes. BSA-blocked magnetic beads were added, and the antigen-phage complex was bound to the magnetic beads at room temperature for 15 minutes. The beads were washed three times with 1 mL of 1.2 mM CaCl2/TBST (TBST containing 1.2 mM CaCl2), and then further washed twice with 1 mL of 1.2 mM CaCl2/TBS (TBS containing 1.2 mM CaCl2). Then, 0.5 mL of 1 mg/mL trypsin was added to the beads and the beads were suspended at room temperature for 15 minutes, and then immediately, the beads were separated using a magnetic stand to collect phage solution. The collected phage solution was added to 10 mL of E. coli strain ER2738 in the logarithmic growth phase (OD600: 0.4-0.7). Culturing the E. coli cells by stirring gently at 37° C. for 1 hour infected the E. coli cells with the phages. The infected E. coli cells were seeded into 225×225 mm plates. Then, the phages were collected from the culture medium of the seeded E. coli cells, thereby preparing phage library solution, which was used for a second round of panning.

The second round of panning involved adding 40 pmol of the biotin-labeled antigen to the prepared phage library solution, and performing the same procedure as that in the first round of panning, thereby preparing phage library solution. This prepared solution was used to perform a third round of panning.

The third round of panning involved adding 10 pmol of the biotin-labeled antigen to the prepared phage library solution, and performing the same procedure as that in the first and second rounds of panning to collect the seeded E. coli cells.

Example 9 Evaluation by Phage ELISA

Phage-containing culture supernatants were collected in accordance with a conventional method (Methods Mol. Biol., (2002) 178, 133-145) from the single colonies of E. coli obtained by the above-described method.

The phage-containing culture supernatants, to which skim milk and CaC12 were added, were subjected to ELISA by the following procedure. StreptaWell 96 microtiter plates (Roche) were coated overnight with 100 μL of PBS containing the biotin-labeled antigen. Each well of the plates was washed with PBST to remove the antigen, and then the well was blocked with 250 μL of 0.02% skim milk-TBS for 1 hour or longer. The prepared culture supernatants were added to each well from which 0.02% skim milk-TBS was removed, and the plates were allowed to stand at 37° C. for 1 hour, thereby allowing phage-displayed antibodies to be bound to the antigen present in each well. After washing with 1.2 mM CaC12/TBST, HRP-conjugated anti-M13 antibody (GE Healthcare, 27-9421-01) diluted 25,000 × with 1.2 mM CaCl_(2/)TBS was added to each well, and the well was incubated for 1 hour. After washing with 1.2 mM CaCl_(2/)TBST, TMB solution (LifeTechnologies, 00-2023) was added to each well, the color development reaction of the solution in each well was stopped by the addition of sulfuric acid, and then the color was measured on the basis of absorbance at 450 nm.

The clones subjected to phage ELISA as described above were amplified using specific primers, and nucleotide sequence analysis was performed on these genes. Then, on the basis of the results of phage ELISA and sequence analysis described above, the pool of antibody fragments after the third round of panning was converted to full-length human antibodies for further evaluation.

Example 10 Conversion of Antibody Fragments to Full-Length Antibodies, Expression and Purification

The phagemids were extracted from the E. coli cells collected during the third round of panning, using NucleoBond Xtra Midi Plus (MACHEREY-NAGEL, 740412.50). Then, the antibody variable regions were cut by the restriction enzyme treatment, and ligated to a cassette vector in which an antibody constant region was introduced into a vector carrying EF1 promoter and the replication origin OriP of EBNA1. E. coli DHSα (TOYOBO, DNA-903) was transformed with the ligation products, and full-length antibody plasmids for expression in animal cells were extracted from the obtained single colonies.

Expression of the antibodies was performed using the following method. The human embryonic kidney cell-derived FreeStyle 293-F cell line (Invitrogen) was suspended in FreeStyle 293 Expression Medium (Invitrogen), and the cells were seeded at 190 μL per well of 96-well plates at a cell density of 5.0×10⁴ cells/well. Each of the prepared plasmids was introduced into the cells by lipofection. The cells were cultured for 5 days in a CO₂ incubator (37° C. and 8% CO₂) for secretion of antibodies in the culture supernatants. The secreted antibodies in the culture supernatants were purified using Multi screen HTS GV (Millipore, MSGVN2250).

Example 11 Construction of Human and Mouse PlexinA1-Expressing Cells

Antigen-expressing cell lines were constructed by the following method. A plasmid was prepared by inserting, into pCXND3 vector carrying CAG promoter and a neomycin-resistant gene, a cDNA constructed to express the portion of human PlexinA1 (NCBI Reference Sequence NP_115618.3) or mouse PlexinA1 (NCBI Reference Sequence NP_032907.1) up to the transmembrane region (up to position 1300 in human PlexinA1 and position 1290 in mouse PlexinA1) in which the signal peptide was replaced with HMM+38 (SEQ ID NO: 7), as a protein C-terminally fused with the Myc tag (SEQ ID NO: 51). The amino acid sequence of the prepared human PlexinA1 is shown in SEQ ID NO: 15, and the amino acid sequence of mouse PlexinA1 is shown in SEQ ID NO: 37.

The prepared plasmid was cleaved with restriction enzyme PvuI into a linear form, and then introduced into Ba/F3 cells by electroporation using GenePulserX cell (Bio-Rad). After the introduction, the cells were seeded into 96-well plates by the limiting dilution method, and selected using G418. After 1 to 2 weeks, the selected cells were visually observed for single colony formation in the wells, and a portion of single colony-forming cells were collected and subjected to Western blot analysis using the Myc tag antibody. In parallel with this, the cells were captured onto 96-well plates and fixed with 4% paraformaldehyde, acetone, and methanol, and then ELISA was used to examine whether the Myc tag antibody reacts to the cells having holes in the cell membranes. These results of Western blot analysis and ELISA established that human PlexinA1 and mouse PlexinA1 are expressed in the Ba/F3 cells.

Example 12 Evaluation by Cell ELISA

The antibody supernatants obtained in Example 10 were subjected to cell ELISA by the following procedure. Initially, 384-well plates were prepared, and human PlexinA1- and mouse PlexinA1-expressing Ba/F3 cells were each captured onto the bottom of different wells. After washing each well of the plates with PBS, the prepared antibody supernatants were added at 20 μL/well and allowed to stand at room temperature for 1 hour. Then, each well was washed with 1 M Hepes (pH 7.4), HRP-labeled anti-human IgG antibody (Invitrogen, AHI0304) diluted 5000 × with TBS was added at 20 μL/well, and the mixture was allowed to stand at room temperature for 1 hour. After washing each well of the plates with 1 M Hepes (pH 7.4), the substrate solution (ABTS peroxidase substrate system) was dispensed at 20 μL/well to develop color for 1 hour at room temperature. Then, binding of the antibodies to human PlexinA1 and mouse PlexinA1 was confirmed by measuring absorbance at 405 nm using SpectraMax from Molecular Devices, LLC.

Antibodies having an absorbance of 0.2 or more for human PlexinA1/BaF3 and having an absorbance of 0.2 or more for mouse PlexinA1/BaF3 were selected, and subjected to the in vitro activity evaluation assay described below. By way of example, antibodies exhibiting the absorbance values shown in FIG. 4 and Table 1 were selected as human/mouse cross-reactive PlexinA1 antibodies (hPANL#240 and hPANL#359). The vertical axis in FIG. 4 represents absorbance values (405 nm) measured by cell ELISA, and the values are shown in Table 1. The amino acid sequence of an H chain of hPANL#240 is shown in SEQ ID NO: 9, and the amino acid sequence of an L chain of hPANL#240 is shown in SEQ ID NO: 10 (see also Table 2).

TABLE 1 A405 nm Human PlexinA1/BaF3 Mouse PlexinA1/BaF3 hPANL#240 1.8706 1.8259 hPANL#359 1.9304 2.033

TABLE 2 hPANL#240 QVQLQQSGPGLVKPSQTLSLTCAISGD H Chain SLSSTSAAWNWIRQSPSGGLEWLGRTY (SEQ ID NO: 9) YRSKWYNDYAVSVKSRITINPDTSKNQ FSLQLNSVTPEDTSVYYCARDRGYYNG VDVWGQGTMVTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKV DKKVEPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVD YSHEDPEVKFNWYYDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTIPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSP hPANL#240 SYELTQPPSVSVSPGQTASITCSGDKL L Chain GDKYASWYQQRPGQSPLLVIYQDNKRP (SEQ ID NO: 10) SGIPQRFSGSNSGNTATLTISGTQAMD EADYFCQAWDSGTFVFGTGTKVTILRQ PKANPTVTLFPPSSEELQANKATLVCL ISDFYPGAVTVAWKADGSPVKAGVEIT KPSKQSNNKYAASSYLSLTPEQWKSHR SYSCQVTHEGSTVEKTVAPTECS

Example 13 Affinity Maturation of Selected Antibody

hPANL#359 selected in Example 12 was subjected to affinity maturation, using a method known to those skilled in the art. Specifically, with reference to, for example, (Biochemical and Biophysical Research Communications, (2000), 275, 2, 553-557), a new library was prepared by substituting the light chain of the antibody with a human light chain library, and then the library was subjected to two rounds of the panning procedure against biotin-labeled human PlexinA1. Phage-containing culture supernatants were collected from the obtained single colonies of E. coli, and subjected to phage ELISA in the same manner as described above.

Nucleotide sequence analysis was performed on E. coli cells of the clones that showed color development in the antigen-immobilized wells by phage ELISA. Furthermore, the phagemids were extracted from the E. coli cells, and introduced into an animal cell expression vector. Then, the vector was introduced into the FreeStyle 293-F cell line (Invitrogen) by lipofection to obtain culture supernatants in which antibodies were secreted.

Example 14 Confirmation of Binding Capacities of Acquired Antibodies

Binding capacities of the antibody culture supernatants prepared in Example 13 to human PlexinA1 were confirmed using OctetRED384 (ForteBIO). Specifically, the antibody culture supernatants diluted to 1.25 μg/mL were immobilized onto Protein G biosensors (ForteBIO), and human PlexinA1 was subsequently applied thereto, for measurement of binding responses between the antibodies immobilized onto the biosensors and the antigen.

As a result, several types of antibodies confirmed to be bound to human PlexinA1 were acquired. 359B2-2-3-6 (H chain, SEQ ID NO: 11, L chain, SEQ ID NO: 12) is an antibody having an improved binding capacity compared to the parent antibody before affinity maturation.

TABLE 3 359B2-2-3-6 QVQLVQSGAEVKKPGASVKVSCKASGY H Chain TFTSYYMHWVRQAPGQGLEWMGIINPS (SEQ ID NO: 11) CGSTSYAQKFQGRVTMTRDTSTSTVYM ELSSLRSEDTAVYYCARAPGHYYYGMD VWGQGTTVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVNTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDK KVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQV YTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFSCSVMH EALHNHYTQKSLSLSP 359B2-2-3-6 SYELTQPPSVSVSPGQTASITCSGDKL L Chain EDKYASWYQLKPGHSPVLVIYQDSKRP (SEQ ID NO: 12) SGIPERFSGSNSGNTATLTISGTQAMD EADYYCRAWDSNTGDVVFGGGTKLTVL RQPKAAPSVTLFPPSSEELQANKATLV CLISDFYPGAVTVAWKADSSPVKAGVE TTTPSKQSNNKYAASSYLSLTPEQWKS HRSYSCQVTHEGSTVEKTVAPTECS

Furthermore, mouse chimeric antibodies (hPANL#240-mFc: H chain, SEQ ID NO: 13, L chain, SEQ ID NO: 10; 359 B-2-2-3-6-mFc: H chain, SEQ ID NO: 14, L chain SEQ ID NO: 12) produced by the below-described method from these antibodies acquired from the human antibody naive library, as well as immunized rabbit-derived mouse chimeric antibodies (PXB693-mFc: H chain, SEQ ID NO: 45, L-chain, SEQ ID NO: 46; PXB727-mFc: H-chain, SEQ ID NO: 47, L-chain, SEQ ID NO: 48; PXB361 b-mFc: H chain, SEQ ID NO: 49, L chain, SEQ ID NO: 50) were evaluated for their human/mouse cross-reactivity, using OctetRED384 (ForteBIO). Note that the L chains of the antibodies derived from the human antibody naive library were not chimerized.

Specifically, the antibodies adjusted to 10 ␣g/mL by 10 × diluted HBS-EP+ (GE healthcare, BR-1006-69) were immobilized onto Protein G biosensors (ForteBIO), and human and mouse PlexinA1 adjusted to 260 nM with HBS-EP+were applied thereto. The Protein G biosensors were regenerated using 10 mmol/L Glycine-HCl, pH 1.5 (GE Healthcare, BR-1003-54). After the measurement, analytical software Data analysis 7.0 (ForteBIO) was used to compute amounts of binding (FIG. 5). These results showed that PXB361b, PXB693, and PXB727 exhibit binding affinities only for mouse PlexinA1, and hPANL#240 and 359B2-2-3-6 are human/mouse cross-reactive antibodies. In FIG. 5, the vertical axis represents amounts of binding to human and mouse PlexinA1.

TABLE 4 hPANL#240-mFc QVQLQQSGPGLVKPSQTLSLTCAISG H Chain DSLSSTSAAWNWIRQSPSGGLEWLGR (SEQ ID NO: 13) TYYRSKWYNDYAVSVKSRITINPDTS KNQFSLQLNSVTPEDTSVYYCARDRG VYNGVDYWGQGTMVTVSSAKTTAPSV YPLAPYCGDTTGSSVTLGCLVKGYFP EPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAH PASSTKVDKKIEPRGPTIKPCPPCKC PAPNLRRGPKVFIFPPKIKDVLMISL SPIVTCVVVDVSEDDPDVQISWFVNN VEVHTAQTQTMREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNNKDLPAPIE RTISKPKGSVRAPQVYVLPPPEEEMT KKQVTLTCMVTDFMPEDIYVEWTNNG KTELNYKNTEPVLDSDGSYFMYSKLR VEKKNWYERNSYSCSVVHEGLHNHHT TKSFSRTPGK 359B2-2-3-6-mFc QVQLVQSGAEVKKPGASVKVSCKASG L Chain YTFTSYYMHWVRQAPGQGLEWMGIIN (SEQ ID NO: 14) PSGGSTSYAQKFQGRYTMTRDTSTST YYMELSSLRSEDTAVYYCARAPGHYY YGMDVWGQGTTVTVSSAKTTAPSVYP LAPVCGDTTGSSVTLGCLVKGYFPEP VTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPA SSTKVDKKIEPRGPTIKPCPPCKCPA PNLRNGPKVFIFPPKIKDVLMISLSP IVTCVVVDVSEDDPDVQISWFVNNVE VHTAQTQTHREDYNSTLRVVSALPIQ HQDWMSGKEFKCKVNNKDLPAPIERT ISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKT ELNYKNTEPVLDSDGSYFMYSKLRVE KKNWVERNSYSCSVVHEGLHNHHYYK SFSRTPGK

Example 15 Production of Mouse Chimeric Antibodies

The heavy chain variable regions of the antibodies were amplified with specific primers, and the amplified products were cloned, together with mouse heavy chain constant region fragments, into a restriction enzyme-linearized animal cell expression vector, using In-Fusion HD Cloning Kit (Takara Bio). A mouse IgG2a-derived heavy chain constant region was used for hPANL#240, 359B-2-2-3-6, PXB693, and PXB727, and a mouse IgG1-derived heavy chain constant region was used for PXB361b.

Furthermore, the light chain variable regions of PXB693, PXB727, and PXB361b were amplified with specific primers, and the amplified products were cloned, together with a mouse light chain constant region, into a restriction enzyme-linearized animal cell expression vector, using In-Fusion HD Cloning Kit (Takara Bio).

The heavy chain expression vectors carrying the mouse constant region and the human light chain sequence expression vectors or the light chain expression vectors carrying the mouse constant region were introduced into the FreeStyle 293-F cell line (Invitrogen) by lipofection. The cells were cultured for 5 days in a CO₂ incubator (37° C., 8% CO₂, 90 rpm), and then the antibodies were purified from the culture supernatants obtained above by a method known to those skilled in the art, using rProtein A Sepharose™ Fast Flow (Amersham Biosciences). Absorbance at 280 nm was measured using a spectrophotometer for the purified antibody solutions, and antibody concentrations were computed from the measured values, using extinction coefficients computed by the PACE method (Protein Science, (1995) 4, 2411-2423).

Example 16 Epitope Binning

Regarding the five types of mouse chimeric antibodies (PXB361b-mFc, PXB693-mFc, PXB727-mFc, hPANL#240-mFc, and 359B2-2-3-6-mFc) prepared in Example 15, it was verified whether any pair of these antibodies can bind to the antigen, mouse PlexinA1, without competing, by using Octet RED 384 (ForteBIO). The five types of mouse chimeric antibodies can be grouped according to epitope, by verifying the competition pattern. This was accomplished with reference to a common epitope binning technique (mAbs (2012) 5: 2, 270-278).

Specifically, the five types of antibodies (assumed as antibodies A to E) adjusted to 10 μg/mL as “Ab1” were immobilized onto five Protein G biosensors, respectively. Mouse PlexinA1 adjusted to 260 nM was applied thereto. Then, the antibody A as “Ab2” was bound to the five sensors on which the five types of “Ab1” were immobilized. After regeneration of the Protein G biosensors using 10 mmol/L Glycine-HC1, pH 1.5 (GE Healthcare, BR-1003-54), the five types of “Ab1” were again immobilized onto the sensors, the antigen was applied thereto, and then the antibody B as “Ab2” was bound to the sensors. This procedure was repeated until the antibody E, while regenerating the biosensors.

Analytical software Data analysis 7.0 (ForteBIO) was used to compute the parameters. If the antibodies A and B compete with each other, no binding response of the antibody B to the antigen bound to the immobilized antibody A is observed. If the antibodies A and B do not compete with each other, an elevated binding response of the antibody B to the antigen bound to the immobilized antibody A can be confirmed.

The competition ratio of the antibody B relative to the antibody A (FIG. 6) was evaluated as the value determined by dividing the value obtained by subtracting {the binding response of the antigen bound to “Ab1; antibody A”} from {the binding response 200 seconds after the binding of “Ab2; antibody B” to the antigen}, by {the immobilization response of “Ab1; antibody B” to the Protein G biosensor}. PXB693 was used as Ab2.

The results revealed that PXB361b acquired as an antagonist antibody does not compete with the other four antibodies acquired as agonist antibodies. Furthermore, the four types of agonist antibodies (PXB693, PXB727, hPANL#240, and 359B2-2-3-6) were shown to compete with one another.

Example 17 Construction of Evaluation System for Semaphorin 3A Activity against U87-MG Cells by Using xCELLigence System

An assay was performed using the xCELLigence system (ACEA) to evaluate the action of semaphorin 3A protein in human cells. The xCELLigence system can evaluate morphological changes, migration, and the like, on the basis of electrical impedance produced on the cell adhesion surface and on microelectrodes arranged on the bottom of a special plate. The assay was performed by the following method.

U87-MG cells of a human glioblastoma cell line cultured in 5% FBS-containing EMEM medium (ATCC) were used. U87-MG cells were seeded at a density of 1×10⁴ cells/well in the E-plate 96 (ACEA), which is a special plate for the xCELLigence system, and cultured at 37° C. for 12 to 24 hours. Then, human semaphorin 3A was diluted with 5% FBS-containing EMEM medium to a suitable concentration and added to the cell culture medium, and the Cell index value for each well was measured by the xCELLigence system (ACEA). Cell index values measured 1 hour after the addition of semaphorin 3A are shown in FIG. 7. A semaphorin 3A-induced concentration-dependent decrease in Cell index value was confirmed. Note that the Cell index value was used as an index of the size of cell morphology and/or the cell adhesion strength.

Example 18 Evaluation of Activities of Anti-Mouse PlexinA1 Antibodies

Activities of the prepared anti-mouse PlexinA1 antibodies and anti-human/mouse PlexinA1 antibody were evaluated using the mouse semaphorin 3A-dependent mouse bone marrow-derived dendritic cell contraction assay system described in Example 2. Specifically, mouse bone marrow-derived dendritic cells were seeded into 96-well plates at 2×10⁴ cells/well in RPMI1640 medium containing FBS and mouse GM-CSF, and cultured at 37° C. for 12 to 24 hours. The anti-mouse PlexinA1 antibodies and anti-human/mouse PlexinA1 antibody, an anti-KLH antibody of the same isotype as a control, and mouse semaphorin 3A were diluted to a suitable concentration with 10% FBS-containing RPMI1640 medium, and then added to the cell culture medium and the mixtures were cultured at 37° C. for 5 hours. Then, dendritic cell contraction was quantified using the method described in Example 2, and then evaluated. The results are shown in FIG. 8. The anti-mouse PlexinA1 antibodies (PXB693-mFc and PXB727-mFc) and the anti-human/mouse PlexinA1 antibody (359B2-2-3-6-mFc) were confirmed to promote dendritic cell contraction in a concentration-dependent manner, and exhibit the same activity as semaphorin 3A signaling.

Example 19 Evaluation of Activities of Anti-Human/Mouse PlexinA1 Antibodies

Activities of the prepared anti-human/mouse PlexinA1 antibodies were evaluated using the human semaphorin 3A activity measurement system with the aid of the xCELLigence system as described in Example 17. U87-MG cells were seeded at a density of 1×10⁴ cells/well in the E-plate 96 (ACEA), which is a special plate for the xCELLigence system, and cultured at 37° C. for 12 to 24 hours. The anti-human/mouse PlexinA1 antibodies and an anti-KLH antibody of the same isotype as a control were diluted to a suitable concentration with 5% FBS-containing EMEM medium and added to each well, and then the Cell index value for each well was measured 1 hour after the addition to the well. The results are shown in FIG. 9. The anti-human/mouse PlexinA1 antibodies (hPANL#240 and 359B2-2-3-6) were confirmed to reduce the Cell index in a concentration-dependent manner, and exhibit the same activity as semaphorin 3A signaling.

Example 20 Preparation of Mouse PlexinA1 Sema Domain Recombinant Protein

A mouse PlexinA1 sema domain protein gene was designed on the basis of the sequence of NCBI Reference Sequence NP 032907.1 to encode a sequence in which the signal peptide (from the N-terminus to isoleucine at position 24) was replaced with artificial signal peptide HMM+38 (SEQ ID NO: 7), and the FLAG tag (SEQ ID NO: 5) and the termination codon were added after serine at position 512. This gene was prepared by gene synthesis. The amino acid sequence is shown in SEQ ID NO: 38. The prepared gene was incorporated into an expression vector and then introduced into FreeStyle293 cells from Invitrogen for expression, and the mouse PlexinA1 sema domain protein was purified from the culture supernatant by affinity purification using anti-FLAG M2 antibody affinity gel (Sigma-Aldrich) and gel filtration chromatography.

Example 21 Preparation of Mouse PlexinA2 Sema Domain Recombinant Protein

A mouse PlexinA2 sema domain protein gene was designed on the basis of the sequence of NCBI Reference Sequence NP 032908.2 (SEQ ID NO: 53) to encode a sequence in which the signal peptide (from the N-terminus to glycine at position 31) was replaced with artificial signal peptide HMM+38 (SEQ ID NO: 7), and the FLAG tag (SEQ ID NO: 5) and the termination codon were added after serine at position 510. This gene was prepared by gene synthesis. The amino acid sequence is shown in SEQ ID NO: 39. The prepared gene was incorporated into an expression vector and then introduced into FreeStyle293 cells from Invitrogen for expression, and the mouse PlexinA2 sema domain protein was purified from the culture supernatant by affinity purification using anti-FLAG M2 antibody affinity gel (Sigma-Aldrich) and gel filtration chromatography.

Example 22 Preparation of Mouse PlexinA1/A2 Sema Domain Chimeric Protein

A mouse PlexinA1/A2 sema domain chimeric protein gene was designed on the basis of the sequence of NCBI Reference Sequence NP_032907.1 to encode a sequence in which the signal peptide (from the N-terminus to isoleucine at position 24) was replaced with artificial signal peptide HMM+38 (SEQ ID NO: 7), and a sequence from arginine at position 459 to serine at position 510 of the mouse PlexinA2 sema domain protein, the FLAG tag (SEQ ID NO: 5), and the termination codon were added to a sequence after isoleucine at position 458 of the mouse PlexinA1 sema domain protein. This gene was prepared by gene synthesis. The amino acid sequence is shown in SEQ ID NO: 40. The prepared gene was incorporated into an expression vector and then introduced into FreeStyle293 cells from Invitrogen for expression, and the mouse PlexinA1/A2 sema domain protein was purified from the culture supernatant by affinity purification using anti-FLAG M2 antibody affinity gel (Sigma-Aldrich) and gel filtration chromatography.

Example 23 Identification of Binding Site Regions of Anti-PlexinA1 Antibodies

The mouse chimeric antibodies PXB693-mFc (mouse IgG2a), PXB727-mFc (mouse IgG2a), and PXB361b-mFc (mouse IgG1) prepared in Example 15, as well as a KLH antibody of the same isotype as each antibody were bound to Protein G-immobilized magnetic beads, and then reacted with the protein solutions prepared in Examples 20 to 22. The reacted magnetic beads were collected, and then a 4 times diluted sample buffer (containing 3-mercapto-1,2-propanediol, Wako Pure Chem) was added and the proteins were heat treated. The three types of mouse PlexinA1 sema domain proteins and the proteins released from the beads were resolved by SDS-PAGE, transferred to the PVDF membrane, and then reacted with alkaline phosphatase-labeled anti-FLAG antibody (Sigma-Aldrich) using iBind Western System (Life Technologies). Then, the proteins of interest were detected using BCIP-NBT Solution Kit (Nacalai Tesque). The Western blot results are shown in FIG. 10. The results revealed that the agonist antibodies (PXB693-mFc and PXB727-mFc) recognize the underlined region shown in FIG. 11 of the amino acid sequence of PlexinA1. This region corresponds to the underlined region of the human PlexinA1 sema domain shown in FIG. 12. The homology between the underlined human PlexinA1 sema domain and mouse PlexinA1 sema domain is considerably high; therefore, on the basis of the above-described data, the anti-human Plexin-A1 agonist antibodies of the present invention are believed to exhibit agonistic action and effects by binding to the epitope present in the underlined region of human Plexin-A1. Note that a human PlexinA1 sema domain recombinant protein, a human PlexinA2 sema domain recombinant protein, and a human PlexinA1/A2 sema domain chimeric protein can be created with reference to the description in Examples 20 to 22, and the method described in Example 23 can be used to confirm the region bound by hPANL#240 or 359B2-2-3-6.

SEQUENCE LISTING FREE TEXT

SEQ ID NO: 1: Amino acid sequence of mouse semaphorin 3A recombinant protein

-   SEQ ID NO: 2: Amino acid sequence of human semaphorin 3A recombinant     protein -   SEQ ID NO: 3: Amino acid sequence of human Plexin-A1 (NCBI Reference     Sequence NP_115618.3) -   SEQ ID NO: 4: Amino acid sequence of human Plexin-A1 recombinant     protein -   SEQ ID NO: 5: FLAG tag sequence -   SEQ ID NO: 6: Amino acid sequence of the signal peptide of human     Plexin-A1 -   SEQ ID NO: 7: Amino acid sequence of artificial signal peptide     HMM+38 -   SEQ ID NO: 8: Amino acid sequence of EBNA1 -   SEQ ID NO: 9: Amino acid sequence of an H chain of human/mouse     cross-reactive PlexinA1 antibody hPANL#240 -   SEQ ID NO: 10: Amino acid sequence of an L chain of human/mouse     cross-reactive PlexinA1 antibody hPANL#240 -   SEQ ID NO: 11: Amino acid sequence of an H chain of human/mouse     cross-reactive PlexinA1 antibody 359B2-2-3-6 -   SEQ ID NO: 12: Amino acid sequence of an L chain of human/mouse     cross-reactive PlexinA1 antibody 359B2-2-3-6 -   SEQ ID NO: 13: Amino acid sequence of an H chain of mouse chimeric     human/mouse cross-reactive PlexinA1 antibody hPANL#240-mFc -   SEQ ID NO: 14: Amino acid sequence of an H chain of mouse chimeric     human/mouse cross-reactive PlexinA1 antibody 359B2-2-3-6-mFc -   SEQ ID NO: 15: Amino acid sequence of human Plexin-A1 recombinant     protein -   SEQ ID NO: 16: Amino acid sequence of soluble mouse PlexinA1 protein -   SEQ ID NO: 17: Rabbit antibody H chain constant region sequence -   SEQ ID NO: 18: Rabbit antibody L chain constant region sequence -   SEQ ID NO: 19: Amino acid sequence of an H chain variable region of     anti-mouse PlexinA1 antibody PXB361b -   SEQ ID NO: 20: Amino acid sequence of an L chain variable region of     anti-mouse PlexinA1 antibody PXB361b -   SEQ ID NO: 21: Amino acid sequence of an H chain variable region of     hPANL#240 -   SEQ ID NO: 22: Amino acid sequence of an L chain variable region of     hPANL#240 -   SEQ ID NO: 23: Amino acid sequence of H chain CDR1 of hPANL#240 -   SEQ ID NO: 24: Amino acid sequence of H chain CDR2 of hPANL#240 -   SEQ ID NO: 25: Amino acid sequence of H chain CDR3 of hPANL#240 -   SEQ ID NO: 26: Amino acid sequence of L chain CDR1 of hPANL#240 -   SEQ ID NO: 27: Amino acid sequence of L chain CDR2 of hPANL#240 -   SEQ ID NO: 28: Amino acid sequence of L chain CDR3 of hPANL#240 -   SEQ ID NO: 29: Amino acid sequence of H chain CDR1 of 359B-2-2-3-6 -   SEQ ID NO: 30: Amino acid sequence of H chain CDR2 of 359B-2-2-3-6 -   SEQ ID NO: 31: Amino acid sequence of H chain CDR3 of 359B-2-2-3-6 -   SEQ ID NO: 32: Amino acid sequence of L chain CDR1 of 359B-2-2-3-6 -   SEQ ID NO: 33: Amino acid sequence of L chain CDR2 of 359B-2-2-3-6 -   SEQ ID NO: 34: Amino acid sequence of L chain CDR3 of 359B-2-2-3-6 -   SEQ ID NO: 35: Amino acid sequence of an H chain variable region of     359B2-2-3-6 -   SEQ ID NO: 36: Amino acid sequence of an L chain variable region of     359B2-2-3-6 -   SEQ ID NO: 37: Amino acid sequence of mouse Plexin-A1 recombinant     protein -   SEQ ID NO: 38: Amino acid sequence of mouse PlexinA1 sema domain     recombinant protein -   SEQ ID NO: 39: Amino acid sequence of mouse PlexinA2 sema domain     recombinant protein -   SEQ ID NO: 40: Amino acid sequence of mouse PlexinA1/A2 sema domain     chimeric protein -   SEQ ID NO: 41: Amino acid sequence of an H chain variable region of     anti-mouse PlexinA1 antibody PXB693 -   SEQ ID NO: 42: Amino acid sequence of an L chain variable region of     anti-mouse PlexinA1 antibody PXB693 -   SEQ ID NO: 43: Amino acid sequence of an H chain variable region of     anti-mouse PlexinA1 antibody PXB727 -   SEQ ID NO: 44: Amino acid sequence of an L chain variable region of     anti-mouse PlexinA1 antibody PXB727 -   SEQ ID NO: 45: Amino acid sequence of an H chain of mouse chimeric     anti-mouse PlexinA1 antibody PXB693 -   SEQ ID NO: 46: Amino acid sequence of an L chain of mouse chimeric     anti-mouse PlexinA1 antibody PXB693 -   SEQ ID NO: 47: Amino acid sequence of an H chain of mouse chimeric     anti-mouse PlexinA1 antibody PXB727 -   SEQ ID NO: 48: Amino acid sequence of an L chain of mouse chimeric     anti-mouse PlexinA1 antibody PXB727 -   SEQ ID NO: 49: Amino acid sequence of an H chain of mouse chimeric     anti-mouse PlexinA1 antibody PXB361b -   SEQ ID NO: 50: Amino acid sequence of an L chain of mouse chimeric     anti-mouse PlexinA1 antibody PXB361b -   SEQ ID NO: 51: Myc tag sequence -   SEQ ID NO: 52: Amino acid sequence of mouse PlexinA1 (NCBI Reference     Sequence NP 032907.1) -   SEQ ID NO: 53: Amino acid sequence of mouse PlexinA2 (NCBI Reference     Sequence NP 032908.2) 

1. An anti-Plexin-A1 agonist antibody.
 2. The antibody according to claim 1, which has a class 3 semaphorin-like activity.
 3. The antibody according to claim 2, wherein the class 3 semaphorin-like activity is a semaphorin 3A-like activity.
 4. The antibody according to claimer 3, wherein the class 3 semaphorin-like activity is an activity to promote dendritic cell contraction or glioma cell contraction.
 5. The antibody according to claim 4, which specifically binds to an epitope in a sema domain of Plexin-A1.
 6. The antibody according to claim 5, wherein the epitope in the sema domain is an epitope in a C-terminal region of the sema domain.
 7. The antibody according to claim 6, wherein the C-terminal region is for binding to residues 461 to 514 of SEQ ID NO: 3 or residues 459 to 512 of SEQ ID NO:
 52. 8. The antibody according to claim 7, which cross-reacts with human Plexin-A1 and mouse Plexin-A1.
 9. The antibody according to claim 8, which is a monoclonal antibody.
 10. The antibody according to claim 9, which is a chimeric antibody, a humanized antibody, or a human antibody.
 11. The antibody according to claim 10, which is Fab, scFv, F(ab′)2, a single-chain antibody, or a bispecific antibody.
 12. A pharmaceutical composition comprising the antibody according to claim 1 and a pharmaceutically acceptable carrier.
 13. A method for producing a pharmaceutical composition comprising mixing the antibody according to claim 1 and a pharmaceutically acceptable carrier.
 14. The pharmaceutical composition according to claim 12, which is for use in prevention and/or treatment of a disease associated with a quantitative or qualitative decrease in function of a class 3 semaphorin.
 15. A kit comprising the antibody according to claim 1 and instructions for administering the antibody for preventing or treating a disease associated with a quantitative or qualitative decrease in function of a class 3 semaphorin.
 16. A kit comprising the pharmaceutical composition according to claim 12 and instructions for administering the pharmaceutical composition for preventing or treating a disease associated with a quantitative or qualitative decrease in function of a class 3 semaphorin.
 17. A method of treating or preventing a disease associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, said method comprising administering an effective amount of the antibody according to claim 1 to a subject in in need thereof.
 18. The method of claim 17, wherein the disease is an autoimmune disease, inflammatory disease or cancer.
 19. The method of claim 18, wherein the autoimmune disease is a member selected from the group consisting of pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus.
 20. A method of treating or preventing a disease associated with a quantitative or qualitative decrease in function of a class 3 semaphorin, said method comprising administering an effective amount of the pharmaceutical composition according to claim 12 to a subject in in need thereof.
 21. The method of claim 20, wherein the disease is an autoimmune disease, inflammatory disease or cancer.
 22. The method of claim 21, wherein the autoimmune disease is a member selected from the group consisting of pruritus due to psoriasis and atopic dermatitis, allergic rhinitis, osteoporosis, rheumatoid arthritis, and systemic lupus erythematosus. 